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Genome instability represents one of the leading forces driving the onset and 
development of cancer. It arises as a consequence of the combined effect of DNA damage 
and errors made by the DNA repair system. In many cancers, DNA damage tolerance and 
DNA repair pathways are disrupted or deregulated, thereby promoting cancer 
progression. DNA repair also appears to play a substantial role in cancer therapy response. 
This Dissertation Thesis was performed in response to several unclear and unresolved 
issues of the role of DNA damage and DNA repair in cancer pathogenesis. 
The aim of the Thesis was to search for potential novel biomarkers and confirmation of 
the validity of already existing biomarkers related to DNA damage and DNA repair, 
which may be associated with cancer susceptibility and patient's clinical outcome. We 
also explored the biological basis of different biomarkers and their associations. 
The major outcomes of this Thesis are: 1) The elevated chromosomal aberrations (CAs) 
in peripheral blood lymphocytes (PBLs) may serve as a biomarker of cancer susceptibility 
and partially affects patients' clinical outcome. While telomere shortening contributes to 
the formation of CAs in PBLs only in healthy individuals, less efficient DNA double-
strand break repair in PBLs is associated with telomere shortening only in cancer patients. 
2) Several genetic variants in DNA repair genes and their gene-gene interactions have 
been discovered that modulated the levels of CAs in PBLs. In genome-wide associations 
studies, several new genetic variants associated with CA frequency in PBLs were also 
indicated. 3) The associations of several genetic variants in DNA repair genes with cancer 
susceptibility and patient's clinical outcome have been identified. The importance of 
studying DNA repair at a functional level, directly in tumour and non-malignant tissue, 
has been pointed out to reveal its potential predictive and prognostic value. 
In conclusion, this Dissertation Thesis suggested and/or verified several potential 
candidate biomarkers associated with cancer susceptibility and patients' clinical outcome 
for further use in population monitoring and clinical use. However, additional studies on 
larger independent populations and performing functional tests are needed to replicate 




Nestabilita genomu představuje jednu z předních sil, která řídí vznik a rozvoj 
nádorového onemocnění. Vzniká v důsledku kombinovaného účinku poškození DNA  
a chyb způsobených opravným systémem DNA. V mnoha nádorech jsou tolerance  
k poškození DNA a opravné dráhy DNA narušeny nebo deregulovány, což podporuje 
jejich progresi. Oprava DNA také hraje významnou roli v odpovědi na léčbu nádorových 
onemocnění. Tato disertační práce vznikla v reakci na několik nejasných a nevyřešených 
otázek úlohy poškození DNA a opravy DNA v patogenezi nádorových onemocnění. 
Cílem práce bylo hledání potenciálních nových biomarkerů a potvrzení platnosti již 
existujících biomarkerů souvisejících s poškozením DNA a opravou DNA, které mohou 
být spojeny s náchylností ke vzniku nádorových onemocnění a klinickým výsledkem 
pacienta. Také byl zkoumán biologický základ různých biomarkerů a jejich vzájemné 
vztahy. 
Hlavní výstupy této práce jsou: 1) Zvýšené hladiny chromozomálních aberací (CA)  
v lymfocytech periferní krve (PBL) mohou sloužit jako biomarker náchylnosti ke vzniku 
nádorových onemocnění a částečně ovlivňují klinický výsledek pacientů. Zatímco 
zkracování telomer přispívá k tvorbě CA v PBL pouze u zdravých jedinců, méně účinná 
oprava dvouřetězcových zlomů DNA v PBL je spojena se zkrácením telomer pouze  
u pacientů s nádorovým onemocněním. 2) Bylo objeveno několik genetických variant  
v genech zapojených do opravy DNA a jejich vzájemné interakce, které ovlivňovaly 
hladiny CA v PBL. Celogenomové asociační studie také naznačily několik nových variant 
spojených s frekvencí CA v PBL. 3) U několika genetických variant v genech pro opravu 
DNA byl identifikován jejich vztah s náchylností ke vzniku nádorových onemocnění  
a klinickým výsledkem pacienta. Zároveň byla zdůrazněna důležitost studia opravy DNA  
na funkční úrovni, a to přímo v nádorové a přilehlé nenádorové tkáni za účelem odhalení 
její potenciální prediktivní a prognostické hodnoty. 
Závěrem, tato disertační práce navrhla a/nebo ověřila několik potenciálních kandidátních 
biomarkerů spojených náchylností ke vzniku nádorových onemocnění a klinickým 
výsledkem pacientů pro jejich další použití při monitorování populace a v klinické praxi. 
Pro potvrzení našich výsledků a k odhalení biologických mechanismů je však zapotřebí 




This Dissertation Thesis consists of an overview of the research I have been involved in 
during the time of my PhD studies and which were published between 2015 and 2020. 
These include eight original research articles (Publications I–VII) and four review articles 
(Publications IX–XII) summarizing the problematics published in the original research 
articles. All publications, either related or unrelated to this Thesis are shown in detail in 
section "Publication activity". Publications I–XII in extenso are presented in Annexes of 
this Thesis. 
1.1 Cancer: An overview 
1.1.1 Causes of and risk factors for cancer and its development 
Cancer is a general term for a large group of diseases, whose causes, characteristics and 
occurrence can vary. It develops as a consequence of the complex interactions between 
various factors, and therefore, it is commonly called as a complex (previously 
multifactorial) disease. These factors include lifestyle factors (alcohol consumption, 
tobacco smoking, poor diet, lack of physical activity, or being overweight and obese), 
ageing, environmental and occupational exposure (chemicals and other substances), food 
contaminants, exposure to ultraviolet (UV) and ionizing radiation (IR), infectious agents 
(some viruses and bacteria), certain hormones, chronic inflammation, 
immunosuppression, genetic susceptibility, and family history of cancer [1, 2] (Figure 1). 
Malignant tumours are triggered and developed through the multistep process of 
carcinogenesis. The nature of this process is the genetic (e.g. point mutations and 
chromosomal rearrangements) and/or epigenetic (e.g. DNA methylation, microRNA) 
changes and their accumulation over time leading to malignant transformation of a normal 
cell into a tumour cell [3]. The primary cause of carcinogenesis is the change in crucial 
genes, also called as "driver" genes. These include proto-oncogenes, tumour suppressor 
genes, and DNA repair (mutator) genes [4]. 
Apart from this long-lasting dogma of gradual tumour evolution by the acquisition of 
genetic and/or epigenetic changes over time, a new concept of tumour formation called 
"chromothripsis" was formulated. This phenomenon challenged this dogma and was first 
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described by Stephens et al. in 2011 [5]. Chromothripsis is characterized by massive 
chromosomal rearrangements arising all at once in localised and confined genomic 
regions in one or a few chromosomes. If the occurrence of such an event is on the upper 
limit of what a cell can tolerate, the cell can withstand and survive such a destructive 
event [6]. Today, other unanticipated catastrophic events leading to the same or similar 
consequences, i.e. to sudden multiple changes in the genome, are known and the most 
recent reviews confer on details [7, 8]. 
In 2000 and a decade later, Hanahan and Weinberg published their reviews summarizing 
the hallmarks of cancer [9, 10]. These reviews have managed to persist at the core of 
literature about cancer biology, serving as blueprints for understanding the core traits of 
cancer. However, Lazebnik in his review article from 2010 argued that "cancer" is often 
used to refer to malignant tumours and a "hallmark" is a distinguishing feature [11]. He 
subsequently pointed out that the only true hallmark of cancer is the invasion and 
metastasis since other original hallmarks are characteristic for both benign and malignant 
growths. The revisiting the hallmarks of cancer published in 2017 concluded to organize 
the dense complexities of cancer biology into seven major hallmarks: i) selective growth 
and proliferative advantage, ii) altered stress response favouring overall survival 
(including DNA repair, apoptosis, autophagy, and senescence), iii) vascularization, iv) 
invasion and metastasis, v) metabolic rewiring, iv) abetting microenvironment, and vii) 
immune modulation [12] (Figure 1). Thus, it is obvious that the field of cancer biology is 
still evolving and despite the rapid progress in its understanding, there are still questions 




Figure 1. Causes of and risk factors for cancer and its development along with seven revisited hallmarks 
of cancer (modified according to [12]). 
Different factors (in blue) continuously interact with cells (in orange) leading to transformative alterations in genetics/epigenetics, 
alterations in chromosomal numbers and structure, and heterotypic interactions (in green) which, along the pathways towards 
malignancy, undergo cycles of evolution and clonal selection leading to the acquisition of cancer-competent traits, so-called the 
hallmarks of cancer (in red). 
 
1.1.2 Cancer incidence and mortality 
Affecting almost all types of tissues in the human body, cancer represents one of the most 
severe health burdens in the world. According to the World Health Organization 
estimates, cancer causes more than 8.9 million deaths every year. With the increase in 
incidence by 28 % between 2006 and 2016, there were 17.2 million new cancer cases 
worldwide in 2016 [13, 14]. The International Agency for Research on Cancer released 
the New Global Cancer Data about estimates of cancer incidence and mortality, which 
have predicted 18.1 million new cancer cases (17.0 million excluding non-melanoma skin 
cancer) and 9.6 million cancer deaths (9.5 million excluding non-melanoma skin cancer) 
in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer 
(11.6 % of the total cases) and the leading cause of cancer-related deaths (18.4 % of the 
total cancer deaths), closely followed by breast, colorectal, prostate, and stomach cancer 
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Figure 2. The most common cancer types worldwide in 2018 (modified according to [16]). 
Percentages mean the proportions of individual cancer type incidence/mortality of all new cancer cases/cancer deaths. 
 
The Czech Republic is ranking in the top 20 countries for the cumulative risk of incidence 
worldwide. On the contrary, due to the high quality of health care, the cumulative risk of 
cancer mortality decreases. As a consequence, the Czech Republic is 41st in terms of 
cancer mortality compared to other countries around the world [15] (Figure 3). According 
to the latest data published by the Institute of Health Information and Statistics of the 
Czech Republic on web portal www.svod.cz [17], both incidence and mortality of the 
three most common cancers worldwide decrease in the Czech Republic over time, except 
for the incidence of breast cancer (Figure 4:A1-3). When looking at the age structure of 
the patient populations, lung and breast cancers are most often diagnosed in individuals 
in the category of age between 65 and 69, while colorectal cancer incidence is highest in 
the age category between 70 and 74 (Figure 4:B1-3). Moreover, breast cancer is also 
commonly diagnosed in younger individuals aged 35 to 50 years. However, the tumour-
node-metastasis (TNM) stage at which the tumour is diagnosed is critical for increasing 
the success rate of the treatment of cancer patients. Lung cancer is mainly diagnosed at 
the TNM stage IV, while the vast majority of breast cancer patients are diagnosed at early 
TNM stages (I+II). More than half of colorectal cancer patients are diagnosed at late TNM 
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Figure 3. The estimated cumulative risk of incidence and mortality for all cancers, both sexes, and ages 0-
74 for different countries in 2018 (adopted from [18]). 
Cumulative incidence/mortality is defined as the probability or risk of individuals getting/dying from the disease over a specified age-
span. Cumulative risk is expressed as the number of cases/deaths per 1000 person-years that are expected to occur in a given population 
between the specified age limits (e.g. between birth and the age 74 years) if the cancer rates were as those observed in the specified 









Figure 4. The incidence and mortality rates over time and the age structure of the patient populations for 
the three most commonly diagnosed cancers – lung (A-B1), breast (A-B2), and colorectal (A-B3) for the 
Czech Republic (adopted from [17]). 
Figures A1-3 represent the course of incidence (blue line) and mortality (red line) over time. Figures B1-3 represent the age structure 
of the patient populations for incidence for individual cancer types. All data are for the Czech Republic. The ASR is a weighted mean 
of the age-specific rates where the weights are taken from the population distribution of a standard population; the ASR is expressed 
per 100,000. Comparison of rates referring to different time periods or different geographical areas is only possible after considering 
the differences in the age structure of the underlying populations. The age-standardisation allows the comparison of the rates that are 
arithmetically adjusted to have the same age structure of the standard population [19]. Abbreviations: ASR-W – age-standardised rate 
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1.1.3 Cancer prevention strategies 
Apart from the primary prevention which purpose is to prevent a disease from ever 
occurring (via limitation of risk exposure or increasing the immunity of individuals at risk 
of the disease), the secondary (the screening programs) and tertiary (the therapy 
strategies) prevention are essential as well [20]. 
Secondary prevention (the screening programs): An essential criterion for the treatment 
efficacy of all cancer types is their early diagnosis, preferably still in the pre-cancerous 
stages. Therefore, there is an increasing tendency across developed countries to 
implement screening programs in standard healthcare [21]. Unfortunately, general lung 
cancer screening is currently not available in the Czech Republic. However, the Czech 
standard healthcare provides breast cancer screening for a non-risk female population 
aged over 45 at two-year intervals since 2002. There are also special dispensary programs 
for women at very high risk of breast cancer development [22]. In 2008 and 2009, the 
Ministry of Health of the Czech Republic launched a nationwide screening program 
aimed at the early detection of cervical and colorectal cancer, respectively. Cervical 
cancer screening is designed for all adult women in one-year intervals [23]. Colorectal 
cancer screening is available for all people aged between 50 and 54 once per year (the 
faecal occult blood test), and for all people aged over 55 every ten years (the colonoscopy) 
[24]. 
Tertiary prevention (the therapy strategies): Once a malignant disease is diagnosed, 
current practice to choose and implement the therapy for cancer patients is primarily 
based on the tumour location, TNM stage, and results from tumour histopathological 
examination (tumour type). Other factors, such as patient's age and general condition, 
associated diseases, etc. are also taken into consideration. The treatment regimens 
substantially differ for lung, breast, and colorectal cancer patients as well as for other 
cancer types. In all cancer types, surgical removal of the tumour represents the 
fundamental treatment method. Therefore, if possible, surgeons always try to remove all 
tumour tissue mass. Other main treatment strategies include chemotherapy, radiation 
therapy, targeted therapy, and hormone therapy [21]. The recent success of 
immunotherapy strategies such as immune checkpoint blockade in several malignancies 
has established the role of immunotherapy in the treatment of cancer as well [25]. In 
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leukaemia, lymphoma and myeloma, also stem cell or bone marrow transplants are 
applied as a cancer treatment [26] (Figure 5). 
 
 
Figure 5. Cancer treatment options (adopted from [27]). 
 
Although all the levels of cancer prevention are significantly developing, the tools for 
their implementation are often less specific and less sensitive, usually invasive, and 
inconvenient for patients. As a consequence, tumours are often diagnosed at advanced 
stages of the disease, and not all patients benefit from cancer treatment and often suffer 
from severe adverse effects caused by therapy. Searching for new tools in the form of 
molecular biomarkers that can be easily collected (for instance, from blood) thus 
represents the most attractive approach in the era of personalized medicine. To bring a 
more in-depth insight into this issue, the next two chapters will focus on biomarkers and 
their role in cancer research and clinical practice. 
1.2 Introduction to biomarkers 
1.2.1 Definition of biomarkers 
Biological markers (biomarkers), also called molecular markers and signature molecules 
[28], have been defined by Hulka et al. in 1990 as "cellular, biochemical or molecular 
alterations that are measurable in biological media, such as human tissues, cells, or 
fluids" [29]. Indeed, there are plenty of more accurate definitions of biomarkers in the 
literature which substantially overlap [30-32]. Nevertheless, the World Health 
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Organization has stated that a true definition of biomarkers includes "almost any 
measurement reflecting an interaction between a biological system and a potential 
hazard, which may be chemical, physical, or biological. The measured response may be 
functional and physiological, biochemical at the cellular level, or a molecular 
interaction" [33]. 
1.2.2 Study of biomarkers 
Biomarkers have been used by generations of epidemiologists, physicians, and scientists 
to study human diseases. Until the 1990s, available technologies only allowed analysing 
individual proteins or genes, alternatively their very finite groups. Traditionally, 
biomedical research has been hypothesis-driven; investigators put forth hypotheses and 
design experiments to test them. Advances in laboratory techniques have given rise to 
more technology-driven research. Rather than putting forth a hypothesis, investigators 
apply high-throughput methods to biological systems and look for exciting results that 
could lead to hypothesis generation for further testing. Both hypothesis-driven and 
technology-driven approaches are applicable to biomarker discovery [34]. Despite 
numerous published studies on biomarkers every year, the relatively low number of those 
is actually used in clinical practice. There are several causes; however, they mainly reside 
in the biomarker's own development process [35, 36]. Specifically, consideration of 
methodological issues regarding the design, conduct, analysis, and interpretation of the 
results is fundamental to address a research question appropriately [37]. The main reasons 
for biomarker failures are summarized in the review by Pavlou et al. [38]. 
Because of the critical role of biomarkers at all stages of the disease, their development 
involves multiple processes. From initial discovery, they must undergo rigorous 
evaluation, including analytical validation, clinical validation, and assessment of clinical 
utility prior to incorporation into routine clinical care [39-41]. Concerning the properties 
of all mentioned types of biomarkers, an ideal biomarker should meet the following 
criteria: it should be reliable, highly sensitive and specific, robust, accurate, reproducible, 
cheap, and the biological sample for its evaluation should be easy to collect. Moreover, 
its metabolism should be clearly understood, it should be chemically stable, and no 
circadian or day to day variation should not occur for its validation [38]. 
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Biomarkers can be measured in several human biological specimens, typically with the 
use of biochemical, molecular, and cytogenetic techniques. They can be detected in the 
circulation (whole blood, serum, or plasma) or excretions or secretions (urine, stool, 
saliva, ascites, cerebrospinal fluid, sputum, or nipple discharge), and thus easily assessed 
non-invasively and serially. Alternatively, they can be tissue-derived and require either 
biopsy or specialized imaging for evaluation [42, 43]. Genetic/Germline biomarkers can 
be inherited and detected as sequence variations in germline DNA isolated from whole 
blood, sputum, or buccal cells, or can be somatic, and identified as mutations in DNA 
derived from tumour tissue [39]. 
1.2.3 Types of biomarkers 
Depending on the property, biomarkers can be divided into two main groups: molecular 
and classical biomarkers. Molecular biomarkers are substances and biomolecules that 
form a genome, epigenome, transcriptome, proteome or metabolome (Figure 6). They can 
be further classified as nucleic acids (e.g. genes, genetic variations, mRNAs, microRNAs, 
or other non-coding RNAs), proteins (e.g. enzymes, receptors, and antibodies), hormones, 
peptides, metabolites, etc. A molecular biomarker can also represent a collection of 
alterations (altered structure or function), such as gene expression, and proteomic and 
metabolomic signatures. Classical biomarkers are the morphological and functional 
characteristics of the phenome (e.g. size, histology and grading of the tumour, presence 
of invasion, mitosis, metastasis, results of functional imaging examinations, age, sex, 
patient's comorbidity, etc.) [36, 44, 45]. From classical biomarkers, a typical example of 
a complex biomarker is the TNM classification [46]. 
In terms of origin, we can divide biomarkers according to the biological levels at which 
the measurements were performed: cell (''cellome''), tissue (''tissueome''), organism 
(''organome''), and population (''populome'') (Figure 6). In oncology, it is further 
distinguished whether the biomarker originates from the tumour (biomarkers associated 
with cancer/tumour, cancer/tumour biomarkers) or from its host (host-associated 
biomarkers) [34, 44, 47]. 
The most frequently used classification of biomarkers in clinical practice is based on their 
function. These types of biomarkers describe their association with the patient and his/her 




Figure 6. Biogenesis of biomarkers (modified according to [34, 47]). 
 
1.3 Molecular cancer epidemiology 
1.3.1 Implementation of molecular cancer epidemiology 
High-throughput technologies have significantly led to a rapidly increasing use of 
molecular biomarkers as such and in epidemiological studies, i.e. in a field known as 
"molecular epidemiology" [48-51]. In 1982, Perera and Weinstein proposed "molecular 
cancer epidemiology" as a new paradigm for cancer research [52]. Based on the concept 
that there is a continuum between exposure to an external agent(s), its/their metabolism 
within the human body, and the onset of time-delayed disease (such as cancer), molecular 
cancer epidemiology is heading toward uncovering the "black box" of traditional 
epidemiology by searching for molecular biomarkers. Biomarkers can be focused on 
different stages of the onset and/or the development of the disease. We can distinguish 
three main types of biomarkers that are able to address the internal process of interaction 
between the external agent and the human body. These include 1) Biomarkers of 
exposure/internal dose, 2) Biomarkers of early biological effect, and 3) Biomarkers of 
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Biomarkers of susceptibility are unique since they may include all the mentioned types of 
biomarkers. They cover inherited and acquired genetic susceptibility, epigenetic 
modifications as well as alterations in physiological structures and functions induced by 
age, pathological conditions, and lifestyle factors, and may lead to different phenotypic 
manifestation [55]. Mainly inherited genetic susceptibility may play a role in influencing 
the individual response to exogenous exposures in a complex gene-environment 
interaction [56]. Therefore, understanding of which genetic variants, genotoxic changes, 
epigenetic profiles, and host factors may affect the susceptibility to cancer onset, 
progression and/or response to therapy appear to be essential to get insights into the still 
not well-understood exposure-disease continuum. 
Biomarkers also have many valuable applications in disease detection and monitoring of 
the patient's health status. Therefore, the three types of biomarkers mentioned above could 
be supplemented with the fourth group, 4) Biomarkers of the disease (Cancer 
biomarkers). This group is usually used, among others, in oncology in terms of clinical 
utility; however, it is not commonly classified as one of the main groups of biomarkers. 
It can be further divided into five subgroups: 4A) Screening biomarkers, 4B) Diagnostic 
biomarkers, 4C) Prognostic biomarkers, 4D) Predictive biomarkers, and 4E) Biomarkers 
for monitoring [43] (described in detail in the following paragraphs). All the mentioned 




Figure 7. An overview of different types of biomarkers used in molecular cancer epidemiology (updated 
according to [43, 53, 57]). 
Figure summarizes three main classes of biomarkers used in molecular cancer epidemiology, supplemented by the fourth group 







































































































































































































































































































































































































































































































































































































































































































1.3.2 Cancer biomarkers 
Cancer (tumour) biomarkers refer to substances that are defined as "molecules which 
indicate the presence of cancer or provides information about the likely future behaviour 
of cancer, i.e. likelihood of progression or response to therapy" [58]. A challenge of 
cancer biomarker study is to translate the molecular-biological information into advances 
in patient's care [59]. Biomarkers can be used for cancer patient assessment in various 
clinical settings, including estimating risk of developing cancer (Biomarkers of 
susceptibility, also called as Biomarkers of risk assessment), screening for primary occult 
cancers (Screening biomarkers, also called as Detection biomarkers), distinguishing 
benign from malignant tumours or one type of malignancy from another (Diagnostic 
biomarkers), determining the prognosis of patients (Prognostic biomarkers), prediction 
of response to treatment (Predictive biomarkers), and monitoring status of the disease, 
either to detect recurrence or progression of the disease (Biomarkers for monitoring) [39] 
(Figure 8). 
The use of biomarkers in oncology has been much more extensive than in other diseases 
for more than 30 years [60]. Over the past ten years, there have been almost 34,400 
publications indexed in PubMed with the joint headings of "cancer" and "biomarker" in 
Title/Abstract [61]. Before the genomic era, most biomarkers used in clinical practice 
represented protein-based biomarkers which are still widely used. Although these 
biomarkers are cheap and easy to measure, they do not evince sufficient specificity and 
sensitivity and should be supplemented or even replaced by nucleic acid-based 
biomarkers in the future. In the following paragraph, examples of individual cancer 
biomarkers (mainly for solid cancers) currently used in the clinical practice are described. 
 
 
Figure 8. An overview of different types of cancer biomarkers (modified according to [62]). 
 





























1.3.3 Cancer biomarkers currently available in clinic 
Biomarkers of susceptibility: Identification of individuals who are at an increased risk of 
developing cancer is the goal of the risk assessment. This is currently possible with 
genetic testing for known cancer-related syndromes. The identification of many of the 
genes predisposing to hereditary cancer syndromes has been established within the past 
15 years [63, 64]. Examples of predisposing genes for hereditary cancer syndromes 
include BRCA1/2 (hereditary breast and ovarian cancer), APC (familial adenomatous 
polyposis), MLH1, MSH2, MSH6, PMS1, and PMS2 (hereditary non-polyposis colorectal 
cancer), MUTYH (colorectal cancer associated with familial adenomatous polyposis), 
MEN1 (multiple endocrine neoplasia type 1), RET (multiple endocrine neoplasia type 2), 
RB (retinoblastoma), and CDK4 and CDKN2A (familiar melanoma) [65]. Consequently, 
genetic testing for cancer susceptibility can be carried out within high-risk families. 
Screening biomarkers: One of the greatest challenges in oncology nowadays is the 
detection of cancer at an early stage, which means at a potentially treatable stage. Indeed, 
the development of screening (or early detection) biomarkers is currently one of the 
highest priorities in cancer research. Unfortunately, these types of biomarkers possess 
insufficient sensitivity for small tumours or premalignant lesions and lack of specificity 
in general. These features limit the use of the most available biomarkers in population-
based screening for early malignancy [66, 67]. Despite these issues, several biomarkers 
have undergone evaluation for cancer screening, since they are usually cheap and easy to 
measure. Indeed, a few biomarkers are currently widely used in asymptomatic people for 
a screening of early cancer, i.e. prostate-specific antigen (PSA) for prostate cancer [68, 
69], the faecal occult blood test for colorectal cancer [70], and Human Papilloma Virus 
testing (Pap smear) for cervical cancer [71]. 
Diagnostic biomarkers: Diagnosis, contrary to screening, involves patients with specific 
symptoms, which may or may not be due to cancer. In general, serum protein biomarkers 
contribute little to the early diagnosis of cancer, mainly due to the lack of both sensitivity 
and specificity. However, serum biomarkers may aid in the differential diagnosis of 
benign and malignant diseases in a small number of cases. Specifically, serum cancer 
antigen (CA) 125 is as an adjunct in differentiating between benign and malignant pelvic 
masses (ovarian cancer) in postmenopausal women [72-74]. Serum human epididymis 
protein 4 has superior specificity to CA 125, especially in premenopausal women, and 
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may be used similarly as CA 125 as a diagnostic aid in women with pelvic masses [74]. 
Another biomarker that can aid cancer diagnosis, in this case, hepatocellular cancer 
detection, is alpha-fetoprotein (AFP) [75]. Besides, AFP is also used to screen patients at 
high-risk of hepatocellular cancer [76]. 
Prognostic biomarkers: Following diagnosis and surgical removal of the primary 
tumour, the essential questions to be addressed for patient management are i) how 
aggressive is the tumour, and ii) is necessary to administrate the adjuvant (i.e. post-
operative) systemic therapy. Thus, if a tumour is deemed to be indolent (i.e. growing 
slowly), the patient may be able to avoid receiving adjuvant treatment. On the other hand, 
if it is identified as being potentially aggressive and life-threatening, the patient would be 
recommended to have additional therapy, such as adjuvant chemo(radio)therapy. Until 
recently, histological and clinical criteria mainly aided in addressing the above questions. 
However, these criteria are still universally used since a limited number of biomarkers 
have become available to supplement the traditional criteria for determining patient's 
prognosis nowadays. These include, for instance, the tissue-based biomarkers, urokinase-
type plasminogen activator, and plasminogen activator inhibitor-1 as prognostic 
biomarkers for certain cancer types [77, 78], and Oncotype DX and MammaPrint gene 
expression panels for assessing breast cancer patient's prognosis [79, 80]. Other 
biomarkers widely used to aid the patient's prognosis include AFP, human chorionic 
gonadotropin (HCG), and testicular lactate dehydrogenase in patients with testicular 
cancer (non-seminomatous type) [81], and PSA in patients with prostate cancer [82]. 
Also, BRAF mutations are indicative of patients' poor outcome in metastatic colorectal 
cancer [83]. 
Predictive biomarkers: Therapy predictive biomarkers aim for prospective identification 
of patients who are likely to respond or be resistant to specific treatments. The necessity 
of predictive biomarkers is substantiated by the fact that patients with tumours of the same 
organ type respond very differently to a specific drug. Therefore, response rates for 
unselected patients with various advanced cancer types to currently available systemic 
therapies vary from < 10 % to > 90 % [79, 84]. Many of the newer biological or molecular 
therapies, in particular, have efficacy in only a minority of unselected patients (< 10 %). 
This finding, when combined with the high costs of some of these drugs, illustrates the 
importance of having accurate therapy predictive biomarkers. In recent years, several new 
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predictive biomarkers entered clinical use, and their measurement is mandatory prior to 
the administration of appropriate treatment (summarized in [65]). These include tissue 
biomarkers such as oestrogen/progesterone and HER2 receptors in breast cancer for 
predicting response to endocrine and anti-HER2, respectively; KRAS/NRAS genotyping 
for selecting colorectal cancer patients likely to be resistant to treatment with anti-EGFR 
antibodies; evaluating the microsatellite instability (MSI) status for predicting response 
to 5-fluorouracil (5-FU) in colorectal cancer; BRAF genotyping for predicting response 
to specific BRAF inhibitors in metastatic melanoma; EGFR genotyping and ALK 
rearrangements evaluation for predicting response to EGFR TKI and ALK-inhibitors, 
respectively, in patients with non-small cell lung cancer; and KIT and PDGFRA 
genotyping for prediction of response to c-KIT/PDGFRA inhibitors in gastrointestinal 
stromal tumours [44, 85]. Mutation testing of plasma circulating tumour DNA is likely to 
complement or possibly replace some of the existing biomarkers in the future [86]. 
However, there is still an urgent need to identify predictive biomarkers for specific 
cytotoxic drugs, anti-angiogenic therapies, and immunotherapies. Regarding 
immunotherapy, a recent publication highlighted that mismatch repair (MMR) deficiency 
(so-called MSI-high status) predicts response of solid tumours to immune checkpoint 
blockade with antibodies to programmed death receptor-1 [87]. As well as assessing 
treatment efficacy, predictive biomarkers may also potentially identify upfront an 
optimum drug dose and predict severe toxicities. Nevertheless, there are few validated 
biomarkers for these purposes at present. 
Biomarkers for monitoring: These types of biomarkers may be used to detect 
recurrent/metastatic disease at a potentially curable stage with the assumption that early 
detection of disease recurrence/progression followed by the treatment initiation will result 
in a better patient's outcome than starting treatment when a recurrence is clinically 
evident. Biomarkers identifying early cancer recurrences that are used in clinical routine 
include HCG in trophoblastic malignancy, PSA in prostate cancer, carcinoembryonic 
antigen (CEA) in colorectal cancer, AFP and HCG in patients with germ cell tumours of 
the testis (non-seminomatous type), CA 15-3 in breast cancer, and CA 125 in ovarian 
cancer [88-98]. However, apart from CEA in colorectal cancer, there is little evidence 
that the early detection of recurrent disease and the initiation of new treatment enhances 
patient outcomes [88, 89]. The other purpose of the use of these types of biomarkers is 
the monitoring of patients with advanced cancer receiving systemic therapy. Although 
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imaging methods represent the gold standard for monitoring therapy response in 
oncology, the use of blood-based biomarkers is less expensive, more convenient for 
patients, and applicable in shorter intervals. Biomarkers widely used to monitor the 
therapy comprise the BRC-ABL translocation in chronic myeloid leukaemia, AFP and 
HCG in testicular germ cell cancers, CA 125 in ovarian cancer, PSA in prostate cancer, 
CEA in colorectal cancer, and CA 15-3 in breast cancer [88-98]. 
The concept of this Dissertation Thesis is based on investigating potential cancer 
biomarkers that are related to DNA damage and DNA repair. Therefore, the following 
chapters will be devoted to this subject to provide an overview of the importance of DNA 
damage and DNA repair in the context of cancer susceptibility, cancer development, and 
patient's therapy response and clinical outcome. 
1.4 Genome-maintenance network in preventing malignant 
transformation 
Genome instability is one of the leading forces driving the onset and progression of 
cancer. It is fuelled by DNA damage and errors made by the DNA damage response 
(DDR) system [99, 100]. Since the genome integrity is permanently challenged by DNA 
damaging agents (DDA), eukaryotic cells have evolved the mechanisms on how to deal 
with damaged DNA and limit genome instability. DNA lesions are detected, their 
presence is marked by a specific signal, and consequently, their repair is promoted by a 
variety of complex cellular pathways, which are collectively referred to as the DDR [101, 
102]. The complex DDR system is encoded by almost 200 human genes [103, 104]. Cells 
defective in DDR generally display heightened vulnerability towards DDA, and 
subsequent accumulation of mutations in the genome thus eventually contribute to cancer 
development. On the other hand, unrepaired and excessively accumulated DNA damage 
can be toxic, promoting pathways of cell elimination such as apoptotic and necrotic death 
that are also thought to function as tumour suppressor pathways [105]. 
1.4.1 Sources and types of DNA damage 
Nuclear DNA is continuously exposed to a myriad of DDA that have either endogenous 
or exogenous origin. Regarding endogenous DDA, the majority of the endogenously 
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induced DNA damage arises from the chemically active DNA engaging in oxidative and 
hydrolytic reactions with reactive oxygen species and water, respectively, that are 
naturally present within cells. [106-108]. In addition, non-enzymatic methylation also 
generates nucleobase lesions. DNA strand breaks (SBs) arising from physiological 
processes are caused by abortive topoisomerases activity, and DNA mismatches are 
occasionally introduced during DNA replication [102]. Other endogenous DDA are 
produced by gut microbiota metabolism [109], and some radicals (reactive oxygen and 
nitrogen compounds) are also produced by activated immune cells such as monocytes and 
macrophages as well [110]. 
Exogenous DDA comprise physical, chemical and specific biological agents from the 
environment. Examples include radiation (UV and IR), chemical mutagens (aromatic 
hydrocarbons, halogenated hydrocarbons, aromatic amines, and alkylating agents), high 
temperature, heavy metals (Ni, Cd and As), viruses and certain DDA produced by 
microorganisms, fungi, and plants (e.g., aflatoxin, mitomycin C) [111, 112]. The 
individual DDA causing the specific DNA lesions are summarized in Figure 9A. 
DDA cause damage in DNA nitrogenous bases or its sugar-phosphate backbone. 
Furthermore, some DDA may cause the formation of covalent bonds between DNA 
molecule and proteins (DNA-protein cross-links), thus affecting DNA-histone and DNA-
transcription factor interactions [112]. However, the vast majority of DDA affects the 
primary structure of the DNA double helix, which means that nitrogenous bases 
themselves are chemically modified. It is estimated that out of the 3 × 109 bases in the 
human genome, 25,000 of bases are altered in some way per cell per day [113]. Such 
modifications can, in turn, disrupt the regular helical structure of DNA by the introduction 
of non-native chemical bonds or bulky adducts that do not fit in the standard double helix. 
As a consequence, these lesions cause DNA single-strand breaks (SSBs). Moreover, when 
two SSBs arise in close proximity, or when the DNA-replication apparatus encounters a 
SSB or certain other lesions, DNA double-strand breaks (DSBs) are formed. While DSBs 
do not occur as frequently as the other lesions listed above, they are difficult to repair and 
extremely toxic [114]. If they remain unrepaired, mutations and chromosomal 
rearrangements which are causal events in oncogenic transformation and tumour 





Figure 9. A summary of various DNA damaging agents and types of DNA damage induced (A) along with 
the consequences arising from DNA damage (B) (modified according to [115, 116]). 
Figure 9A summarizes sources and types of DNA damage. Environmental and endogenous sources of DNA damage are shown in 
green boxes, examples of therapeutic DNA damaging agents are shown in yellow boxes, and the types of lesions induced by particular 
agents are shown in grey boxes. Figure 9B summarizes the consequences arising from DNA damage. Abbreviations: 1-mA – 1-
methyladenine, 3-mC – 3-methylcytosine, O6-mG – O6-methylguanine, SAM – S-adenosyl methionine, TMZ – temozolomide, TOPO 
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1.4.2 DNA damage repair systems 
DNA repair represents a complex biological system that comprises several distinct 
pathways repairing different types of DNA damage. Besides, the evidence for extensive 
interactions among proteins involved in distinct DNA repair pathways continues to 
emerge. No single pathway efficiently repairs all types of DNA lesions, and some lesions 
serve as substrates for more than one pathway [117]. Interestingly, if canonical DNA 
repair pathways are deficient, alternative repair mechanisms may be employed to 
compensate for that lack of function [118, 119]. Particular DNA repair pathways include: 
i) repair of base DNA damage by direct reversal DNA repair and base excision repair 
(BER); ii) repair of multiple and bulky base damage by nucleotide excision repair (NER), 
MMR, inter-strand cross-link repair (i.e. Fanconi anaemia (FA) pathway), and translesion 
synthesis; and iii) repair of DNA breaks by SSB repair pathway and DSB repair pathway 
(comprising homologous recombination – HR* and non-homologous end joining – 
NHEJ) [106]. SSB repair and BER are often assumed to be synonymous because they 
involve the same components and are similar after the initial recognition step [115]. 
Individual DNA repair pathways, their function and key enzymes involved are 




Table 1. The summary of DNA repair pathways responsible for repairing the individual DNA lesions along 
with a short description of their function and key genes involved (modified according to [118, 120]). 
 
 
Abbreviations: BER – base excision repair, DSBs – double-strand breaks, FA – Fanconi anaemia, HR* – homologous recombination, 
ICL – inter-strand cross-links, MMR – mismatch repair, NER – nucleotide excision repair, NHEJ – non-homologous end-joining, 
SSBs – single-strand breaks, TLS – translesion synthesis. 









methylated adenosine and 
cytosine 
Direct repair of modified bases by enzymatic 
processes: demethylation.
3 MGMT, ALKBH1
Base excision repair 
(BER) (incl. Short 
patch repair, Long 
patch repair, and SSB 
repair)
Damaged and modified 
bases, SSBs
Monofunctional and bifunctional DNA 
glycosylases and endonucleases excise  
damaged base to generate a basic site. Abasic 
sugars following spontaneous deamination, 
oxidation or alkylation to form SSBs, followed 
by nicking, resynthesis, and SSB repair.
42 OGG1, NEIL1, NEIL2, 
NEIL3, APEX1, PARP1, 
PARP2, XRCC1, POLB, 
LIG1, LIG3, FEN1, PNKP, 
MUTYH
Nucleotide excision 
repair (NER) (incl. 
Transcription-coupled 
NER and Global NER)
Bulky DNA adducts, 
helix‐distorting adducts 
(inter- and intra-strand 
cross-links)
Damage recognition and unwinding of local 
DNA, nuclease excision, resynthesis, and SSB 
repair.
66 RAD23B, DDB1, RPA1, 
RPA2, ERCC1, ERCC2 
(XPD), ERCC3, ERCC5, 
ERCC6, ERCC8, GTF2H1, 
GTF2H2, GTF2H4, 
GTF2H5, GTF2F2, CDK7, 




Base mismatches (single 
nucleotide mutations and 
small insertions/deletions) 
mainly caused by 
replication errors
Recognition and removal of mismatched base 
followed by resynthesis of correct base and 
SSB repair.
27 MLH1, MLH3, MSH2, 
MSH6, PMS2
Inter-strand cross-link 
(ICL) repair, i.e. 
Fanconi anaemia (FA) 
pathway
Inter-strand cross-links Cross-links are excised and then repaired by 
HR (or other mechanisms).
22 BRCA2, FANCA, FANCB, 
FANCC, FANCD2, FANCE, 
FANCG, FANCF, FANCI, 
FANCL, BRIP1, FANCM, 
FAAP20, FAAP100
Translesion synthesis 
(TLS) (DNA damage 
bypass rather than 
repair)
DNA adducts Error-prone polymerases synthesize DNA past 
regions of damage, especially bulky DNA 
adducts (If damaged DNA bases or adducts 
are not repaired before replication has initiated, 
they may stall replication forks, contributing to 
genetic instability. Specialized TLS DNA 
polymerases are recruited to synthesize the 




DSBs Unwinding and resection at DSB to generate 
single-strand end, strand invasion, homologous 
recombination with sister chromatid, 
resynthesis, and resolution. Results in exact 
repair using sequences from sister chromatid.
52 BRCA1, BRCA2, RAD51, 
RAD52 TP53BP1, RBBP8 
(CTIP), EXO1, RPA1, RPA2, 
BLM, PALB2,  MRN 




DSBs Processing and re-ligation of DSB ends. Error 
prone due to processing steps and because the 
homologous template is not used for repair.
27 PRKDC (DNA-PKcs), 
XRCC5 (Ku80), XRCC6 
(Ku70), LIG4, XRCC4, 
POLQ, NHEJ1, DCLRE1C 




1.5 DNA damage and DNA repair in relation to cancer 
Genome instability represents one of the most pervasive characteristics of tumour cells. 
It arises as a consequence of the combined effect of DNA damage, tumour-specific DNA 
repair defects, and a failure to stall or stop the cell cycle before the damaged DNA is 
passed on to daughter cells [10]. Not surprisingly, in many cancers, DNA repair, DNA 
damage tolerance and DDR pathways are disrupted or deregulated, which increases 
mutagenesis and genome instability, thereby promoting cancer progression [121-123]. On 
the other hand, DNA repair appears to play a substantial role in cancer therapy response. 
Therefore, a better understanding of the cellular response to DNA damage will not only 
refill our knowledge of cancer onset and development but also help to refine the cancer 
classification as well as treatment [124]. Based on these findings, a recent study by Chae 
et al. has compiled and analysed a comprehensive list of DNA repair genes utilising the 
large databases Catalogue Of Somatic Mutations In Cancer [125] and The Cancer 
Genome Atlas [126, 127]. The study provided a list of candidate DDR genes that may 
serve as potential biomarkers for genome instability, novel therapeutic targets, or 
predictors of therapy efficacy [103]. 
An integral part of this Dissertation Thesis is a chapter which reflects long-lasting 
(approximately 25 years) experience of our Department with the study of DNA damage 
and repair in relation to cancer as well as the most recent findings, accomplished during 
my PhD studies. In recent years, we have published four review articles on this topic 
(Publications IX–XII), which represent a part of this Thesis, and their content is 
summarized in this chapter. 
1.5.1 DNA damage repair and cancer susceptibility and development 
Each individual has a different risk of developing cancer that is mainly determined by 
genetic background and exposure to carcinogens. Genetic predisposition affects not only 
hereditary forms of cancer but also applies to sporadic tumours, which represent 
approximately 90-95 % of all cancers [128, 129]. Inter-individual differences in DNA 
repair systems may play a role in modulating the individual risk of developing cancer. 
Among the genes playing a role in cancer susceptibility, DNA repair genes are prominent 
candidates as cancer is associated with inherited deficiencies of DNA repair [124]. 
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Alterations in genes involved in DNA repair pathways are associated with the 
development of several malignancies, summarized in [103]. Inactivating mutations and 
hypermethylation in MMR genes (i.e. MSH2, MSH6, MLH1, PMS1, and PMS2) lead to 
the development of hereditary non-polyposis colorectal cancer and MSI, conferring a 
70% lifetime risk of colorectal cancer and an increased risk of developing other cancers, 
such as endometrial, ovary, stomach, small intestine, hepatobiliary tract, upper urinary 
tract, brain, and skin [130]. Germline mutations in BRCA1 and BRCA2, involved in HR* 
and FA repair pathways, increase the risk of developing, among others, breast cancer by 
40-80 % and ovarian cancer by 11-40 % [131]. Moreover, defects in ATM, another gene 
involved in HR* pathway, are associated with ataxia-telangiectasia and up to a 25% 
lifetime malignancy risk, particularly lymphomas and leukaemia as well as other cancers 
[132]. Regarding NER defects, these are responsible for xeroderma pigmentosum, which 
is linked to a 70% risk of skin cancer by eight years of age [133]. 
Nevertheless, it remains ambiguous whether all alterations in DNA repair genes are truly 
causal events in driving tumorigenesis, as mutations in ''mountain'' genes, or are a by-
product of the malignancy and represent more infrequently mutated ''hills'' [134]. In 
support of the former is the "mutator phenotype" and the concept that early mutations in 
critical genes, such as those involved in DNA repair, resulting in genome instability and 
subsequent hypermutability, accounting for the high mutation rate seen in tumours [135]. 
This theory of causality was further supported by studies documenting that MMR 
mutations and MSI are commonly seen in early adenomas and early stages of colorectal 
cancer [136, 137]. 
1.5.2 DNA damage repair and patients' treatment and monitoring 
Cancer treatment strategies, from which the most widely used are chemotherapy and 
radiation therapy, are designed to have cytotoxic effects on rapidly dividing cells (such 
as cancer cells) via induction of DNA damage. In response to induced DNA lesions, the 
DDR machinery allows cells to activate cell cycle checkpoints and proapoptotic signals 
to preserve genome integrity. Depending on the cell or tissue type, persistent genotoxic 
insults could trigger either cellular death by mitotic catastrophe or autophagy or induce a 
replicative stress-induced state of cellular senescence [102]. Although DDR 
dysregulation is causative and permissive of malignant transformation of normal cells and 
cancer progression, it can provide a weakness that can be exploited therapeutically in both 
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conventional cytotoxic therapy and targeted therapy using DDR inhibitors [115, 121, 124, 
138]. Tumour cell sensitivity to chemo- and radiotherapy can highly depend on the 
cellular capacity to repair DNA damage within and between tumour types. Therefore, 
annotation of functional defects in DDR may allow for the development of novel 
prognostic biomarkers as well as could be used to predict therapeutic response, including 
predicting responses following inhibition of DNA repair. 
Several studies found the association of upregulation of DNA repair genes with resistance 
to chemo- and radiotherapy in multiple tumour types [121] and with the tumour's ability 
to metastasize [139, 140]. Thus, while the loss of DNA repair function is significant in 
cancer initiation, the gain of function of similar genes and re-activation of lost DNA repair 
pathways is involved in cancer progression [141, 142]. Targetable DNA repair inhibition 
has been shown to enhance tumour responses to therapy. For instance, PARP1 inhibitors 
are used to treat patients with advanced breast and ovarian cancer harbouring 
BRCA1/BRCA2 deleterious mutations, as loss of BRCA sensitizes these tumours to 
further inhibition of DNA repair resulting in a synthetic lethality [143, 144]. PAPR1 
inhibitors also evince potential in many other cancer types with DNA repair deficiencies 
[145], and inhibition of other DNA repair genes is being evaluated to induce synthetic 
lethality, including PRKDC inhibition in MYC-overexpressing tumours [146]. 
Therapeutic targets encompassing DDR pathways are reviewed in [147]. Besides, the 
emerging field of personalized immunotherapies directed specifically against mutated 
cancer "neo-antigens" may ultimately prove to be strongly linked to impairment in DNA 
repair [148]. 
1.6 Candidate cancer biomarkers associated with DNA damage 
and DNA repair 
This chapter briefly describes those biomarkers studied in this Dissertation Thesis, which 
can serve as potential biomarkers of susceptibility and/or patients' clinical outcome. 
1.6.1 Single nucleotide polymorphisms (SNPs) 
While mutations in DDR genes are associated with high degrees of individual cancer risk, 
these rare events explain only a small fraction of all cancers [149]. Given the importance 
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of DNA damage to cancer development, it is plausible that common variants of DNA 
repair genes would contribute to cancer risk. Such a risk could be measured in large, 
genome-wide association studies (GWAS), or the studies of candidate genes. GWAS 
represent a hypothesis-free (or technology-driven) approach that was applied in 
Publication V and VI. The latter, a hypothesis-based (or hypothesis-driven), approach 
was used in Publication IV and VII. No conclusion has been reached about which of these 
two approaches is more effective/convenient in studying SNPs [150]. 
SNP, a substitution of a single nucleotide occurring in > 1 % within a population, 
represents the most frequently studied type of DNA variation potentially being associated 
with the altered susceptibility to cancer. SNPs are reproducible and possible to measure 
at any point in time (may be used in both prospective and retrospective studies). 
Moreover, the identification of SNPs is becoming increasingly routine, including limited 
genotyping of tumour DNA and screening of somatic (non-tumour) DNA for mutations 
that predispose to cancer or alter treatment response [59]. 
GWAS are feeding into the clinical use of DNA variants and have identified hundreds of 
SNPs and susceptibility loci associated with risk for various cancers [151-161]. 
Nevertheless, only few GWAS have identified cancer susceptibility loci near DNA repair 
genes at stringent levels of significance that have also been shown to function through 
altered DNA repair [156, 159, 161, 162]. These data suggest that common variants in 
DNA repair genes may not make significant contributions to cancer susceptibility and 
that cancer susceptibility may be mostly conferred by high-risk, rare variants within this 
class of genes. However, it is possible that underpowered GWAS could miss common 
variants with weak effect sizes and also, one of the limitations of GWAS is that only 
common SNPs are captured, which by themselves may only contribute a small amount of 
risk to developing cancer. Recently, a pooled analysis of thousands of SNPs in DNA 
repair genes for most common cancers has been performed by analysing data from 32 
GWAS in order to reveal increase the power to detect common variants associated with 
cancer susceptibility [163]. GWAS are also identifying predictors of sensitivity to 
radiation therapy [164] and the pharmacodynamics of anticancer drugs [165]. 
Nevertheless, SNP-based research to identify oncogenic DNA abnormalities remain a 
significant challenge, due to the difficulty of separating these cancer-causing 
abnormalities from genetic and epigenetic "noise" [166]. 
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1.6.2 Chromosomal aberrations (CAs) 
Accumulation of chromosomal abnormalities contributes to genome instability, 
specifically to chromosomal instability. Acquired chromosomal abnormalities can be 
structural or numerical. In the studies involved in this Thesis (Publication I, II, IV, V, and 
VI), we focused on structural chromosomal abnormalities, i.e. CAs in peripheral blood 
lymphocytes (PBLs). Structural CAs arise as consequences of direct mutagenic effect 
and/or due to DNA repair dysfunction [167]. Unrepaired or insufficiently repaired DSBs, 
as well as telomerase dysfunction, are substantial players in the formation of structural 
CAs [168, 169]. Morphologically distinct types of chromosome-type aberrations (CSAs) 
and chromatid-type aberrations (CTAs) emerge depending on the types of clastogens to 
which individuals are exposed and at which stage of the cell cycle SBs appear as primary 
lesions that consequently result in CAs. Usually, G0 or G1 phase-dependent clastogens 
such as IR or bleomycin create DSBs that are either incompletely repaired by NHEJ or 
remain unrepaired and eventually give rise to CSAs, including dicentric and ring 
chromosomes. CTAs include chromatid breaks and exchanges that affect only one 
chromatid of a chromosome. They are induced by chemical or environmental clastogens 
during the S or G2 phase and arise from SBs. These breaks are later converted into DSBs 
possibly through failed or incomplete HR*, giving rise to chromatid breaks [170, 171] 
(Figure 10). 
CAs can be further divided into non-specific and specific. The non-specific CAs that we 
focused on in our studies represent non-recurrent, non-clonal karyotypic alterations. They 
are derived from a single abnormal cell that can remain in the cell for its lifespan and thus 
can be detected by the standard cytogenetic analysis [172, 173]. The specific CAs are 
often recurrent and are analysed by molecular cytogenetic methods, such as sequencing 
and fluorescent in situ hybridization. Many human cancers and neoplastic cells exhibit 
specific CAs, especially translocations and related gene fusions [174]. In the recent past, 
a majority of studies has been focussed on clonal specific CAs as they relate to a specific 
disease or condition and non-specific CAs have been largely ignored since they were 
considered as insignificant genetic "noise" [175]. The evidence linking non-specific CAs 
with cancer is not as overwhelming as it is for specific CAs. However, an examination of 
non-specific CAs in PBLs has been conventionally used in individuals exposed to 
mutagens and potential carcinogens for decades as a surveillance mechanism for 
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genotoxic effect [176-178]. Elevated non-specific CAs in PBLs have been detected 
during the course of cancer evolution, making them an early biomarker of cancer 
susceptibility based on the hypothesis that genetic damage in PBLs reflects similar 
damage in other body cells undergoing carcinogenesis [179, 180]. Therefore, it is 
important to investigate the basis of the origin and the accumulation of CAs both in 
healthy individuals and cancer patients. 
1.6.3 Telomere length (TL) 
Telomeres are unique nucleoprotein structures composed of TTAGGG tandem repeats 
that cap ends of linear eukaryotic chromosomes. In the normal human population, the 
length of telomeres is heterogeneous, ranging between 5 and 15 kb. Also, TL is influenced 
by the genetic background and environmental factors [181]. The telomere complex 
regulates a ''cellular mitotic clock'' and protects chromosomes against exonucleolytic 
degradation, DNA damage and chromosomal instability [182-184]. Telomeres 
progressively shorten through the cellular lifespan. At each cell division, human 
telomeres lose 50-200 bp [185]. The telomeric loss at between 9 and 147 bp per year, 
depending on the organ/tissue has been determined [186]. Telomere shortening can cause 
the proliferation arrest and apoptosis of the cell through the loss of protection at 
chromosome ends. Critically shortened telomeres may be poorly end-capped and 
recognized as DSB by repair machinery [187]. These processes may underlie end-to-end 
chromosome fusions, the initiation of breakage-fusion-breakage cycles, and lead to 
telomere crisis with consequent genome instability that can induce the development of 
numerical and structural chromosomal abnormalities [188-191]. On the other hand, the 
reactivation of telomerase stabilizes telomeres and immortalizes premalignant cells, thus 
enabling cancer progression [192]. Altogether, TL plays a critical role both in genome 
integrity maintenance  [193, 194] and cancer initiation/progression [195, 196] (Figure 
10). There is growing evidence of shorter telomeres caused by low telomerase activity in 
somatic cells being associated with the increased frequency of CAs in PBLs, in particular 
with CSAs [197, 198]. Therefore, we focused on measurement of TL in PBLs in 
Publication II and III to examine whether the telomere shortening contributes to the 
formation of CAs and whether TL may be used as biomarkers on cancer susceptibility 




Figure 10. Sources of chromosomal instability (modified according to [199, 200]). 
Single-stranded DNA damage, if unrepaired, gives rise to DSBs and CTAs. Shortened telomeres may be poorly end-capped and 
recognized as DSBs by repair machinery, resulting in the development of numerical and structural CAs. 
Abbreviations: CAs – chromosomal aberrations; CTAs – chromatid-type aberrations; DSB – double-strand break; SSB – single-strand 
break. 
 
1.6.4 Phenotyping DNA repair as DNA repair capacity (DRC) 
As evident from current knowledge on DNA repair, it represents a multiprotein and 
multistep process which works in a synchronized and coordinated way, together with 
simultaneous participation of DNA damage signalling and cell cycle control. Therefore, 
a real multivariate approach needs to be undertaken to understand this complex system. 
Although the genetic variants of DNA repair genes may provide useful information on 
their association with cancer susceptibility and patient's clinical outcome, their functional 
consequences are usually predicted in silico. Thus, DNA analysis does not provide full 




















did not prove to be sufficiently informative about the overall DRC; several studies have 
reported an inconsistency between transcript level and respective protein quantity [201], 
or actual protein/pathway activity [202, 203]. 
Moreover, genetic predisposition does not exclusively modulate DNA repair activity of 
individuals [204], it is also influenced by environmental and lifestyle factors via various 
mechanisms, such as modulation of the activity of DNA repair enzymes, the pool of DNA 
precursors, and regulation of expression of DNA repair genes [205]. Summarizing all 
mentioned above, a better characterization of DNA repair at the functional level as DRC 
(used in Publication III and VIII), the true phenotypic endpoint that comprises the 
variability of both hereditary and environmental components, gives the information of 
actual DNA repair activity of the cell/tissue/organism [117, 206]. 
 
To conclude the Introduction, the constant increase of cancer incidence and the enormous 
costs of (new) treatments make searching for novel cancer biomarkers a crucial goal in 
order to maintain sustainable public health systems across the world. Carcinogenesis is a 
multistep process, which allows time for active intervention that requires well-defined 
risk classification. Consequently, personalized strategies and specific treatments can be 
applied to cohorts with a documented increased cancer risk. Also, understanding of 
different patients' responses to particular anti-cancer treatment remains insufficient. Since 
each patient is genetically unique, there is a growing need for novel predictive and 
prognostic biomarkers in order to aid oncologists in the selection of optimal type, 
combination and dose of drugs for each patient to improve their outcome and minimizing 
treatment-related toxicity. Further development of these strategies in an efficient and 
timely manner requires investment in the discovery and validation of surrogate cancer 




2. Hypotheses & Aims 
The overall aim of this Dissertation Thesis reflects the current interest in identifying the 
nature and biological regulation of DNA damage and DNA repair and the impact of their 
accumulation and deregulation, respectively, on the cancer development, patients' therapy 
response and clinical outcome. In our studies, we focused on searching for potential novel 
biomarkers related to DNA damage and DNA repair, and on confirmation of the validity 
of already existing biomarkers. We also explored the biological basis of different 
biomarkers and their associations. 
 
The work was divided into three main parts in which the working hypotheses and 
experimental work were driven by these major assumptions: 
1) Genome instability as one of the leading forces driving cancer onset and progression 
is caused by the accumulation of DNA damage and deregulation of DNA repair. 
Therefore, increased levels of chromosomal damage, telomere shortening and inter-
individual variations in DSB repair capacity may play a significant role in the 
individual cancer susceptibility and patients' clinical outcome after diagnosis. 
2) Due to extensive interactions between individual DNA repair pathways, inter-
individual differences in DRC may be caused by genetic variants in different DNA 
repair genes and other related genes and their gene-gene interactions. These genetic 
variants may thus contribute to different levels of chromosomal damage in both in 
disease-free population and occupationally exposed population, as well as in cancer 
patients.  
3) In many cancers, DNA repair pathways are disrupted or deregulated, thereby 
promoting cancer progression. We thus assumed that inter-individual differences in 
DRC might be associated not only with cancer susceptibility, but they may also affect 





Explicitly, we stated the following aims: 
1) To examine whether CAs, TL and DSB repair capacity in PBLs are associated with 
cancer susceptibility and patients' clinical outcome, and also, whether the telomere 
shortening contributes to the formation of CAs and whether inter-individual variation 
in DSB capacity may influence the levels of DNA damage and TL. 
2) To explore the genetic basis of inter-individual variations in CA frequency in PBLs 
and whether it depends on the level and type of exposure by finding novel SNPs 
predisposing to the formation of CAs and potentially to cancer; and to examine 
whether SNPs in DNA repair genes and other genes and their interactions are 
associated with the levels of CAs. 
3) To search for differences in DNA repair in cancer patients which may aid in 
stratifying patients according to predicted therapy response and patients' survival. It 
will lead to an individual approach to patients and may be an attractive target for 





3. Material and Methods 
3.1 Study populations 
All studies included in this Thesis were performed on human biological samples, largely 
on peripheral blood cells and a few of them also on tissue samples. The design of all 
studies was approved by appropriate Ethic committees of participating 
institutions/hospitals. All studies had adhered to the ethical guidelines as set out in the 
Helsinki Declaration – all participants were sufficiently informed about all aspects of the 
study, agreed with the study purpose and procedures to be undertaken (including the 
storage of biological samples and personal data) and provided informed consent. 
Publication I: The study population consisted of three groups of the incident (i.e. newly 
diagnosed) and histologically confirmed individuals with breast (N=158), colorectal 
(N=101), and lung (N=87) cancer, and a group of healthy control individuals without any 
personal cancer history (N=335) from the Czech Republic and Slovakia. All individuals 
were sampled for peripheral blood. Baseline characteristics such as demographics, family 
history of cancer, smoking habit, occupational history, body mass index, and the presence 
of other diseases and drugs received were collected prior to blood collection using a 
structured questionnaire. Moreover, patient disease characteristics, including tumour 
location, TNM stage, histopathological grade, histological classification, and the presence 
of hormonal receptors in breast tumours, were collected after surgical resection. 
Publication II: The study was conducted on almost the same groups of patients and 
healthy control individuals, as in Publication I. The total numbers of cancer patients in 
individual groups only slightly differed: breast cancer patients (N=151), colorectal cancer 
patients (N=96), lung cancer patients (N=90). The number of individuals in the control 
group remained unchanged (N=335). In this study, we also collected the follow-up data. 
Publication III: The study population comprised newly diagnosed and histologically 
confirmed individuals with breast (N=47) and colorectal (N=44) cancer patients and two 
healthy control groups (N=46 and N=44) from the Czech Republic. The individuals were 
sampled for peripheral blood and the same baseline and patient's disease characteristics, 
as in Publication I, were collected. 
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Publication IV: The studied group involved in this study consisted of healthy individuals 
(N=2196) from the Czech Republic and Slovakia. The population comprised individuals 
with defined occupational exposures as well as an unexposed reference group. The 
individuals were sampled for peripheral blood and completed a questionnaire regarding 
the job category, mode and duration of exposure, various exogenous factors (such as 
smoking and dietary habits, alcohol consumption, drug usage, and exposure to X-ray 
radiation) prior to blood collection. 
Publication V: The study population consisted of healthy individuals (N=1473) from the 
Czech Republic and Slovakia, which were divided into two groups based on the 
measurable exposure to genotoxins due to their occupation and smoking habits. The 
exposed and unexposed reference group consisted of 607 individuals and 866 individuals, 
respectively. The individuals were sampled for peripheral blood and completed the same 
questionnaire as in Publication IV. 
Publication VI: The sample set (discovery set) comprised healthy individuals (N=639) 
from the Czech Republic and Slovakia. The subjects consisted of individuals with defined 
occupational exposures as well as an unexposed reference group. The individuals were 
sampled for peripheral blood and completed the same questionnaire as in Publication IV. 
The replication was conducted on two different sample sets. The first replication set 
(replication 1) consisted of 482 individuals (newly diagnosed primary cancer patients – 
described in Publication I, and self-reported smokers). The second set (replication 2) was 
composed of 1288 individuals (occupationally exposed individuals and self-reported 
smokers). All individuals were sampled for peripheral blood. 
Publication VII: This study was carried out on a discovery cohort from the Czech 
Republic comprising newly diagnosed and histologically confirmed individuals with 
sporadic colorectal cancer (N=1832) and healthy control individuals (N=1172), and 
replication cohort from Austria comprising newly diagnosed and histologically confirmed 
individuals with sporadic colorectal cancer (N=950) and healthy control individuals 
(N=820). Patients were sampled for non-malignant colon/rectal tissue or peripheral blood 
and healthy controls for peripheral blood. The same baseline and patient disease 
characteristics, as in Publication I, were collected from both cohort participants, along 
with the type of cancer therapy regimen received and the follow-up data. 
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Publication VIII: The set of patients in this study comprised newly diagnosed and 
histologically confirmed individuals with the sporadic form of colon cancer (N=123) 
from the Czech Republic. For each patient, we have collected paired samples of tumour 
tissue and non-malignant adjacent mucosa (5-10 cm distant from the tumour). The same 
baseline and patient's disease characteristics, as in Publication I, were collected along 
with the type of cancer therapy regimen received and the follow-up data. 
3.2 SNPs analysis 
3.2.1 Selection of candidate SNPs 
The candidate SNPs were selected using different in silico bioinformatic tools to examine 
their functional consequences (Publication IV – SIFT and PolyPhen; Publication V and 
VI – Locus zoom, UCSC genome browser, Haploreg, Regulome DB; Publication VII – 
F-SNP, GERP, SiPhy, ELASPIC and DUET) and according to relevant published 
literature. The SNPs were filtered for their minor allele frequency (MAF > 5-10 % 
depending on the particular Publication) in Caucasian populations to reach an appropriate 
representation of all genotypes in sets of patients and healthy individuals (using 
UK10K—1000 Genomes Project). Besides, functional consequences of highly associated 
SNPs were predicted including their location with respect to the genes in the region, the 
presence of regulatory elements, linkage disequilibrium and expression effects from 
expression quantitative trait loci studies. Individual genes and SNPs, together with their 
selection, are described in detail in the corresponding Publications. 
3.2.2 Genotyping 
Genomic DNA from blood samples was isolated using standard procedures. If the blood 
sample was not available, non-malignant colon/rectal tissue was used to obtain DNA by 
the DNeasy Blood and Tissue Kit (Qiagen). SNPs were determined by Restriction 
Fragment Length Polymorphism technique, TaqMan Allelic Discrimination Assay 
(Applied Biosystems), KASP™ Genotyping Assay (LGC genomics), Axiom Genome-
Wide CEU 1 Array (Affymetrix), and Illumina HumanOmniExpress Exome 8v1.3 chip 




3.3 DNA damage assays 
3.3.1 Evaluation of CAs 
Cytogenetic analysis was performed on cultured PBLs as described in [177, 207-209]. 
Briefly, whole-blood samples were cultured in EKAMTB-100 complete medium with 
phytohemagglutinin (EuroClone S.p.A.), (Publication I, II, and IV), or in RPMI medium 
(Roswell Park Memorial Institute) along with L-glutamine and NaHCO3 (Gibco) 
supplemented with 20% foetal calf serum (Gibco), antibiotics (penicillin and 
streptomycin, Gibco), and phytohemagglutinin (Murex), (Publication V and VI), for 50 
hours at 37°C. After 48 hours of cultivation, cell division was stopped by colchicine 
(Sigma-Aldrich) in the first metaphase of mitosis. After a cytogenetic procedure, 
microscopic slides were stained by conventional Giemsa-Romanowski solution (Sigma-
Aldrich). Microscopical analysis of 100 metaphases with 46 ± 1 chromosomes has been 
blindly performed by two independent scorers. The percentages of aberrant cells (ACs), 
total CAs (CAtot), CTAs (i.e. chromatid breaks and exchanges), and CSAs (i.e. 
chromosome breaks, terminal and interstitial deletions, dicentric and ring chromosomes 
with their difragments, abnormal chromosomes) were detected. Concerning CAs scoring, 
standardization procedure has been applied in former Czechoslovakia (and later in both 
separate countries) [210]. The arbitrary cut-off point between individuals with high and 
low CA frequency, chosen on the basis of long-term experience with this kind of 
biological monitoring in the Czech and Slovak Republics [211], was 2 % for CAtot and 
1 % for CSAs and CTAs. 
3.3.2 Measurement of TL 
TL was measured in Publications II and III as relative telomere length (RTL). Briefly, 
genomic DNA from blood samples was isolated using standard procedures. RTL 
measurement was conducted using the monochrome multiplex PCR assay previously 
described by Cawthon [212] with slight modifications [213, 214]. All details about 
standard and calibration curves, DNA concentrations, negative and quality controls, 
master mix, conditions for telomere sequence, and albumin gene amplification are 
described in Publications III. All reactions were performed in triplicates in an optical 384-
well reaction plate. Real-time PCR experiments were carried out on Viia 7 Real-time PCR 
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System (Applied Biosystems) with the use of two simultaneous programs to acquire the 
respective cycle threshold values for telomere sequences and the albumin gene. RTL was 
expressed as the ratio (T/S ratio) between telomere (T) and albumin (S; single-copy gene). 
3.3.3 γ-H2AX concentration measurement 
This assay documents differences of γ-H2AX levels in human PBLs and was used in 
Publication III. γ-H2AX is a form of histone 2AX that is produced after phosphorylation 
in response to DSBs and apoptosis [215]. Briefly, whole-blood samples were cultured in 
EKAMTB-100 complete medium with phytohemagglutinin (EuroClone S.p.A.) for 72 
hours at 37°C. Five hours before harvesting (late S and G2 phase of the cell cycle), 
bleomycin (Sigma-Aldrich) was added in one of the two cultures; the other culture served 
as a reference. The immobilized γ-H2AX antibody in the wells of a 96-well plate captures 
γ-H2AX from sample lysate. Incubation with an H2AX detecting antibody (Trevigen), 
followed by addition of a Goat anti-mouse horseradish peroxidase conjugate and a 
chemiluminescent horseradish peroxidase substrate yields relative light units that directly 
correlates with the amount of γ-H2AX in the sample. 
3.4 DNA repair assays 
3.4.1 Mutagen sensitivity assay 
Mutagen sensitivity assay (MSA) was performed according to the previously described 
protocol with minor modifications [216] and was used in Publication III. Briefly, two 
whole-blood samples from each subject were cultured for 72 hours in EKAMTB-100 
complete medium with phytohemagglutinin (EuroClone S.p.A.). Five hours before 
harvesting (late S and G2 phase of the cell cycle), bleomycin (Sigma-Aldrich) was added 
in one of the two cultures; the other culture served as a reference. For three hours, cells 
were allowed to repair DSBs caused by bleomycin treatment. Two hours prior to harvest, 
Colcemid (Calbiochem) was added to arrest cells in metaphase. After a cytogenetic 
procedure, microscopic slides were stained by conventional Giemsa-Romanowski 
solution (Sigma-Aldrich). Microscopical analysis of CTAs of 100 metaphases with 46 ± 
1 chromosomes has been blindly performed by two independent scorers. CTAs were 
cytogenetically assessed in samples of all groups after the bleomycin treatment, while not 
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affected samples served for detection of baseline CAs level. Mutagen sensitivity was 
expressed as the average number of CTAs per cell. Cells with ≥ 12 CTAs were assessed 
as those with a high level of chromosome damage, i.e. low DSB repair capacity. 
3.4.2 Comet-based in vitro DNA repair assay 
The comet-based in vitro DNA repair assay is a modified version of the comet assay (also 
known as single-cell gel electrophoresis assay) to assess DRC at the functional level. In 
Publication VIII, specifically BER capacity was measured. Briefly, protein extracts from 
samples were incubated with agarose-embedded substrate nucleoids ("naked" supercoiled 
DNA), containing specifically induced DNA lesions known to be recognised and repaired 
by the BER pathway [217]. During the incubation, BER enzymes contained in the 
samples' extract induced DNA SBs at the sites of specific DNA lesions in the substrate 
nucleoids. The accumulated DNA SBs (repair incisions) were measured after alkaline 
treatment by electrophoresis, similarly as in the case of the standard comet assay [218]. 
DNA loops containing DNA SBs were drawn towards the anode forming a comet-like 
image, subsequently visualised by a fluorescence microscope and analysed using 
semiautomated scoring software. The frequency of DNA SBs (represented by the 
proportion of total DNA in the comet tail) reflected the DRC of the extract. Background, 
treatment and specificity controls were used for all samples to calculate final BER 
capacity. 
3.4.3 Assessment of MSI 
MSI-high status correlates with the loss of expression of the main proteins involved in 
MMR (MLH1 and MSH2) and can, therefore, be used as a marker of a defect in the MMR 
pathway. This approach was used in Publication VIII. DNA for MSI status determination 
was extracted from tumour tissue and non-malignant adjacent mucosa using the DNeasy 
Tissue Kit (Qiagen). MSI status was ascertained using molecular testing of 5 
mononucleotide-repeat markers (BAT 25, BAT 26, NR 21, NR 24, NR 27) run as a 
pentaplex using fluorescently labelled primers [219] and standard PCR chemistry. 
Fragment analysis was performed on ABI 3130 (Applied Biosystems). The final 
comparison between tumour and non-tumour DNA short tandem repeat profiles was 
performed with GeneMapper v4.1 software (Applied Biosystems). A tumour specimen 
was classified as MSI-high when two or more loci were unstable. 
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3.5 Statistical analysis 
Individual studies used different statistical approaches according to the purpose of the 
study and were predominantly performed by an experienced biostatistician. Detailed 
pieces of information are reported in the enclosed Publications I–VIII. Statistical 
significance was set at α = 5 % threshold (P-value = 0.05). In GWAS, regions that were 
highly associated with CA frequency as determined by generally accepted suggestive 
significance threshold of P = 1 × 10−5 and the genome-wide significance threshold of P = 
P = 5 × 10-8 were further analysed with in silico online bioinformatics tools. Multiple 
testing corrections were performed using the Bonferroni test or the Benjamini-Hochberg 
false discovery rate. SNPs frequencies in healthy control individuals were tested for 
Hardy-Weinberg equilibrium. Descriptive statistical analyses were carried out for the 
measured parameters on the whole data set as well as on individual groups. 
In case-control studies, the differences in investigated biomarkers between individual 
groups were tested by nonparametric tests (Mann-Whitney U-test, Kruskal-Wallis test, 
Median Two-Sample). The effect of each studied biomarkers on the cancer risk or the 
effect of SNPs on CA frequencies was determined by (multivariate) logistic and linear 
regressions and was calculated by estimating the odds ratios (ORs) with the 95% 
confidence intervals (CIs). Besides, adjusted ORs (aORs) for potential covariates (age, 
sex, smoking status, and occupational exposure) were used. Meta-analyses for GWAS 
and replication sets was performed, and meta P-values, ORs, effect sizes and 
heterogeneity index were recorded. 
The relationships between individual biomarkers were tested using Chi-square test or 
Spearman's correlation, expressed by Spearman's rho (rs) and graphically plotted by linear 
regression. Clinical outcomes were evaluated by calculating patients' 5-year overall 
survival (OS) and recurrence-free survival (RFS) or event-free survival (EFS). The 
standard Kaplan-Meier definition of events/censored data was used for OS and RFS/EFS 
analysis, depending on the particular study. The relative risk of death or recurrence was 
estimated as a hazard ratio (HR) with 95% CIs, with the use of the Cox regression. 
Moreover, multivariate analyses referred to as a classification & regression tree (CART) 
[220] using Cox regression model to identify the most prognostically significant 
interactions between investigated factors and patients' 5-year OS and RFS/EFS.  
 
 44 
4. Results and Discussion 
The individual parts of this section describe the results we have obtained based on the 
three main aims we have stated. The major findings from each publication (Publications 
I–VIII) included in this Thesis are discussed. 
4.1 CAs, TL and DSB repair capacity and their association with 
cancer susceptibility and patients' clinical outcome 
In this part, we aimed to examine whether CAs, TL and DSB repair capacity in PBLs are 
associated with cancer susceptibility and patients' clinical outcome. Also, we studied 
whether the telomere shortening contributes to the formation of CAs and whether inter-
individual variation in DSB capacity may influence the levels of DNA damage and TL. 
The results are fully documented in attached Publications I–III. 
4.1.1 CAs in PBLs as a biomarker of cancer susceptibility 
First, we aimed to prove the hypothesis that CAs in PBLs may serve as a biomarker of 
cancer susceptibility. The results were published in the cross-sectional study entitled 
"Structural chromosomal aberrations as potential risk markers in incident cancer 
patients." by Vodenkova S et al. (2015) (Publication I, page 92). In this study, we 
evaluated the levels of CAs in PBLs in newly diagnosed colorectal, lung and breast cancer 
patients, and corresponding healthy control individuals. Besides, the attempt to relate CA 
frequencies to the clinicopathological characteristics was addressed for the first time. This 
study represented a free continuation of the study published by our Department in 2010 
[209]. 
One of the major findings of the study identifies significant differences in distributions of 
all types of chromosomal damage in lung and breast cancer patients compared to 
corresponding control groups. In colorectal cancer patients, only CTAs were significantly 
elevated in comparison with controls. Frequencies of chromosomal damage in individual 





Table 2. Frequencies of chromosomal damage in cancer patients and control healthy individuals. 
 
The frequencies of chromosomal damage were tested with the non-parametric Mann-Whitney U-test. The significance level is 0.05. 
Significant values are in bold. aOn the borderline of significance. Abbreviations: ACs – aberrant cells, CAs – total chromosomal 
aberrations, CTA – chromatid-type aberrations, CRC – colorectal cancer, CSA – chromosome-type aberrations, SD – standard 
deviation. 
 
The results of our cytogenetic analysis were further supported by the use of binary logistic 
regression models, documenting the significant association of elevated CA frequencies 
with the susceptibility of particular cancer types. aORs with 95% CIs are summarized in 
Table 3. Elevated ACs, CAs, CTAs and CSAs significantly increased the risk of lung and 
breast cancer (except for CSAs in lung cancer). The only association of increased risk of 
colorectal cancer was found in case of elevated levels of CTAs in our set of patients. Our 
results confirmed the findings from large epidemiological prospective studies 
(summarized by Bonassi et al. [179, 221, 222] and Norppa et al. [223]). While the cohort 
study from Central Europe suggested that CSAs (rather than CTAs) are predictors of 
cancer risk [224], a pooled analysis of thousands of control individuals revealed an 







Table 3. Binary logistic regression models to discern the modulation of incident cancers by chromosomal 
damage end points and major confounders, such as age and smoking. 
 
The significance level is 0.05. Significant values are in bold. Abbreviations: ACs – aberrant cells, aOR – odds ratio adjusted for main 
confounders, CAs – total chromosomal aberrations, CI – confidence interval, CTA – chromatid-type aberrations, CRC – colorectal 
cancer, CSA – chromosome-type aberrations, SD – standard deviation. 
 
Furthermore, we have found significant differences in the distribution of terminal 
deletions between breast cancer patients and female controls (0.39 ± 0.64 vs 0.18 ± 0.41, 
P ≤ 0.05), and the binary logistic regression revealed the association between frequency 
of terminal deletions and the risk of breast cancer (aOR = 1.73, 95% CI = 1.04-2.89, P = 
0.03). Whether this observation is attributable to the importance of DSB repair in the 
etiopathogenesis of breast cancer or is rather representing random finding remains to be 
investigated [171]. 
Since some authors assume that chromosomal damage in PBLs in cancer patients may 
reflect progression (stage) of the tumour rather than being a biomarker of cancer 
susceptibility [226], we, therefore, compared the differences in CA frequencies for 
particular TNM stages and histopathological grades but did not record any association. 
CAs were neither associated with additional clinicopathological characteristics. In 
conclusion, this study supported the concept of using CAs in PBLs as a biomarker of early 
carcinogenic effect and clearly suggested the role of CAs as biomarkers of breast and 
lung cancer susceptibility, whereas their prognostic value warrants further investigation. 
4.1.2 The impact of telomere shortening on the levels of CAs and their 
association with patients' clinical outcome 
The study "Chromosomal damage and telomere length in peripheral blood lymphocytes 
of cancer patients." by Vodenkova S et al. (2020) (Publication II, page 100) represents 
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a free continuation of Publication I. Several years elapsed since its publishing, enabling 
us to focus on the patients' follow-up in the present study. Moreover, we supplemented 
the study by measurement of TL. The primary purpose of this study was to investigate 
the relationship between frequencies of particular types of CAs and TL in PBLs of 
incident cancer patients and corresponding control individuals. Obtained results were 
analysed together with collected baseline, clinicopathological, and follow-up data. 
From descriptive statistics, by comparison of TL between cases and controls, breast 
cancer patients showed significantly longer TL compared to control women (1.54 ± 2.0 
vs 1.88 ± 9.0, P < 0.0001). Moreover, a group of breast cancer patients had the longest 
TL out of all investigated groups (colorectal and lung cancer patients and all control 
individuals). This observation may be explained by the fact that females have longer 
telomeres than males [227]. Several hypotheses have been postulated to clarify this 
association, one of which suggested that this is caused by the presence of oestrogen [228, 
229]. An oestrogen-responsive element is present in a catalytic subunit of the enzyme 
telomerase [230]. Oestrogen may, therefore, stimulate telomerase to add telomere repeats 
to the chromosome ends. It is also known that overexpression of oestrogen is one of the 
typical features of breast tumours and predispose the risk of breast cancer. Indeed, those 
individuals with longer telomeres were at increased risk of breast cancer by 65 % (aOR 
(adjusted for age and sex) = 6.49, 95% CI = 3.00-14.04, P < 0.0001). However, the 
previously published studies, both prospective and retrospective, showed that the 
association of TL in PBLs with breast cancer risk is still conflicting [231-238]. 
Regarding the relationship between CAs and TL, Li et al. [197] and Xu et al. [239] 
provided the evidence that CAs may rather arise as a consequence of telomere shortening 
than as a result of the direct DNA damage. Therefore, we have further correlated TL with 
the frequencies of all types of CAs, and both TL and CAs with age. We have found a 
negative correlation between ACs, CAtot, CSAs and TL in the whole group of controls 
(Figure 11) as well as the negative correlation between TL and age (rs = -0.62, P < 
0.0001). Our data were in accordance with previously published data by Hemminki et al. 
[198]. Nevertheless, except for the correlation between TL and age in control individuals, 
all the remaining statistically significant results should not be over-interpreted as the 
Spearman's rho were small. It means that even if the relationships may be statistically 
significant, they may not be biologically as important. Cancer patients did not exhibit any 
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relationship between either TL and CA frequencies or TL and age, except for lung cancer 
patients (data not shown). It may be probably due to the fact that in complex diseases 
such as cancer, more interactive pathways contribute to the formation of DNA damage 
and chromosomal instability. 
 
 
Figure 11. Spearman's correlation between ACs, CAtot, CTAs, CSAs and TL in control individuals. 
The figure represents the relationships between ACs/CAtot/CTAs/CSAs and TL, which were investigated using Spearman's 
correlation, expressed by Spearman's rho (rs) and graphically plotted by linear regression. CA frequencies are presented on the x-axis, 
and the value of TL expressed as RTL on the y-axis. Abbreviations: ACs – aberrant cells, CAtot – total chromosomal aberrations, 
CSAs – chromosome-type aberrations, CTAs – chromatid-type aberrations, RTL – relative telomere length, TL – telomere length. 
 
Until now, the prognostic value of CAs and TL in PBLs in cancer patients remains unclear 
since conflicting results are reported [240-244]. The hypothesis that different CA 
frequencies and TL variations are determinants of prognosis is plausible to explain the 
heterogeneity in clinical outcomes of cancer patients. In our sets of patients, we did not 
observe any association between any type of CAs and OS or RFS using univariate 
survival analysis. However, outputs obtained from the OS CART analysis showed 
involvement of CTAs in the determination of patients' survival/mortality (Figure 12). 
Regarding TL, we did not find any association of telomere shortening with OS and RFS 































In summary, we provided pilot data on CAs and TL in PBLs in the context of cancer 
susceptibility, patients' prognosis, and long-term survival. We observed that individuals 
with longer TL in PBLs were at increased risk of breast cancer. Accumulation of CTAs 
in PBLs was associated with decreased OS in breast and colorectal cancer patients after 
their stratification according to disease characteristics. In contrast to control individuals, 
cancer patients did not exhibit any relationship between either TL and CA frequencies or 
TL and age. We propose that there is a need to conduct more studies to elucidate the 
association between CAs and TL in PBLs of cancer patients. 
 
 
Figure 12. Overall survival l classification & regression trees for breast (A), colorectal (B), and lung cancer 
(C) patients. 
Classification & regression trees represent the results of multivariate survival analysis (using the Cox regression hazard model). 
Numbers under each node show the total number of cases in a particular subcategory/number of events and percentages of patients 
with 5-year OS. Abbreviations: CART – classification & regression tree, CTAs – chromatid-type aberrations, OS – overall survival, 
TNM – tumour-node-metastasis. 
4.1.3 Variations in DSB repair capacity and their impact on cancer 
susceptibility, chromosomal damage and TL 
Finally, the study "Bleomycin-induced chromosomal damage and shortening of telomeres 
in peripheral blood lymphocytes of incident cancer patients." by Kroupa M et al. (2018) 
(Publication III, page 129) was aimed to employ the mutagen sensitivity for assessment 
of the potential interactions between induced DSBs in PBLs and individual's 
predisposition to breast and colorectal cancer. Inter-individual variations in DSB repair 
capacity were evaluated in vitro utilizing the G2 chromosomal MSA to quantify 
bleomycin-induced CTAs [216]. Besides, we also measured TL and compared mutagen 
sensitivity to γ-H2AX phosphorylation which represents a hallmark of DSB [215]. To our 
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knowledge, this was the first study describing DSB repair capacity in breast and colorectal 
cancer patients in correlation with a shortening of telomeres. 
The mutagen sensitivity has been employed as one of the well-established markers for 
cancer susceptibility [245]. It is expressed as a mean number of CTAs per cell at 
metaphase PBLs and measured by following bleomycin exposure in the G2 phase of the 
cell cycle. Several studies have considered that this functional test may reflect the inter-
individual differences in DRC [216, 245-252]. The reported increased amount of CTAs 
correlates with suboptimal ability to repair DSBs, suggesting that the outcome from MSA 
may reflect DSB repair capacity [253]. 
Results of this study suggested that altered DSB repair in PBLs occurs particularly in 
colorectal patients (158 ± 0.6 vs 130 ± 0.4, P = 0.03). However, the bleomycin sensitivity 
profile of breast patients was similar to that of the control population (data not shown). 
These results were in agreement with Hsu et al. [216] who confirmed that bleomycin 
response profile in PBLs differs in the colorectal, lung, and head/neck cancer patients (but 
not in breast cancer patients) compared to healthy controls. On the other hand, some 
studies have shown strong bleomycin sensitivity not only for familial breast cancer but 
also for sporadic patients [249, 254, 255]. A possible explanation for these discordant 
results could be different aetiology of familial breast cancer as compared to the sporadic 
form and the heterogeneity of breast tumours. Mutated BRCA1 and BRCA2 genes in 
familial breast cancer, which are involved in DSB repair machinery [256], could cause 
higher DNA damage in bleomycin exposed PBLs. Natarajan et al. postulated that 
mutagen sensitivity phenotype is a risk factor for breast cancer [254]. 
Mutagen sensitivity profiles were compared with the measurement of γ-H2AX as a 
hypothesized alternative approach for MSA that is time-consuming. We postulated that 
quantification of chromosomal damage after bleomycin treatment in PBLs might be 
comparable with the concentration of γ-H2AX. Unfortunately, our results did not show 
any correlation between these two approaches. In contrast, the concentration of γ-H2AH 
was higher in colorectal cancer patients who exhibited higher level of CTAs, suggesting 
a lower DSB repair capacity. We thus assumed that γ-H2AX is the first acute response of 
the cell to cope with DSB; however, CTAs are the final results of unrepaired DSBs with 




We further focused on the measurement of TL and the results were used for the study of 
associations between TL and mutagen sensitivity outcomes. We confirmed the 
observation from Publication II that women show longer TL than men (P = 0.0008), and 
therefore, results were adjusted both for age and sex. It has been documented that 
telomere shortening has also been linked to reduced DSB repair capacity [257]. Our 
results showed significant correlation between telomere shortening and mutagen 
sensitivity profile in a pooled group of cancer patients (rs = -0.36, P = 0.02); however, the 
same trend was not detected in a control group. 
In summary, results of this study suggested that altered DSB repair in PBLs is mainly 
associated with colorectal cancer susceptibility. Our results showed a significant 
correlation between telomere shortening and mutagen sensitivity profile in a pooled group 
of cancer patients; however, the same trend was not detected in a control group. Above 
observations added further information to the chain of evidence on the interplay between 
telomere complex and DSB. 
4.2 Genetic basis of inter-individual variations in CA frequency 
In this part, we aimed to explore the genetic basis of inter-individual variations in CA 
frequency in PBLs and whether it depends on the level and type of exposure by finding 
novel SNPs predisposing to the formation of CAs and potentially to cancer. We also 
examine whether SNPs in DNA repair genes and other genes and their interactions are 
associated with the levels of CAs. The results are fully documented in attached 
Publications IV–VI. 
4.2.1 Interactions of SNPs in DNA repair genes and their association with 
CAs 
The study "Interactions of DNA repair gene variants modulate chromosomal aberrations 
in healthy subjects." by Vodicka P et al. (2015) (Publication IV, page 139) was aimed at 
investigating functional variants in DNA repair genes in relation to CAtot, CTAs, and 
CSAs in healthy individuals. DNA repair represents a key player in the formation of 
structural CAs [169] and individual DRC in response to DNA damage, effectively 
preventing an accumulation of CAs, is often modulated by the gene variants in different 
DNA repair pathways [258-260]. Therefore, we examined the hypothesis that SNPs in 
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the BER (XRCC1, hOGG1 and APE1), NER (XPA, XPC, XPD and XPG) and DSB repair 
(XRCC2, XRCC3, NBN and RAD54L) genes and their gene-gene interactions may 
modulate frequencies of structural CAs in a large set of healthy subjects. 
In the whole set of 2196 individuals, the mean ± SD frequencies of CAtot, CTAs and 
CSAs were 1.54 ± 1.54 %, 0.74 ± 0.98 % and 0.80 ± 1.16 %, respectively, with median 
and range being 1 (0-11), 0 (0-6) and 0 (0-10). CAs as well as the constituent CTAs and 
CSAs were significantly increased in occupationally exposed subjects (OR = 2.36, 95% 
CI = 1.97-2.83, P < 0.01; OR = 1.73, 95% CI = 1.45-2.06, P < 0.01; and OR = 1.64, 95% 
CI = 1.38-1.96, P < 0.01, respectively). These observations were in accordance with 
previously published reports for different compounds [177, 207, 261-265]. 
By assessing functional SNPs in individual DNA repair genes, we observed a strong 
association between variant GG genotype in XPD rs13181 and decreased CTA frequency 
(OR = 0.64, 95% CI = 0.48-0.85, P = 0.004; n = 1777 subjects). Our study on such a large 
cohort confirmed our earlier observations on 225 healthy subjects [266] and later study 
on 140 subjects with higher age [267]. XPD represents an important helicase involved in 
NER, which communicates with other DNA repair gene products in dealing with 
exogenous DNA damage [268], but the functional role of XPD rs13181 remains unclear. 
Further, a novel observation was found, a significant association of CT genotype in 
RAD54L rs1048771 with increased CSAs was also observed (OR = 1.96, 95% CI = 1.01-
4.02, P = 0.03; determined in 282 subjects with available genotype). RAD54L exhibits a 
DNA-dependent ATPase and supercoiling activities and plays a role in the HR* pathway 
[269, 270]. However, this association was less robust due to the number of subjects with 
available genotype. Individually, a small risk is irrelevant, but the combination of several 
low-risk alleles can add up to substantial risks, even in the absence of multiplicative 
statistical interactions [271]. 
By addressing pair-wise gene-gene interactions, we have discovered 14 interactions 
significantly modulating CAs, 9 CTAs and 12 CSAs frequencies. Highly significant 
interactions always included pairs from two different pathways. Regarding CAs, 
significant gene-gene interactions were mainly observed for genes involved in BER 
(APE1, hOGG1), NER (XPC, XPD) and DSB repair (XRCC3) together with other DNA 
repair gene variants (NBS1, XRCC2 and XPG). Interestingly, NBS1 rs1805794 appeared 
most often in these interactions; although interactions with BER gene variants resulted in 
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the higher CA frequency, the opposite effect was recorded for the interactions with NER 
gene variants. NBS1 plays an important role in the maintenance of genome integrity by 
being involved in the cellular DDR. The opposite effect on CA frequencies in the 
interplay of NBS1 variants with either BER or NER SNPs is certainly interesting and may 
reflect the specificity of these two excision repair pathways towards different types of 
DNA damage. 
For CTAs, the combinations of homozygous variant genotypes of XPD rs13181 with 
XPG rs17655 (OR = 0.54, 95% CI = 0.34-0.84, P = 0.006) or XRCC1 rs25487 (OR = 
0.68, 95% CI = 0.48-0.96, P = 0.03) genes showed decreased frequencies of CTAs. So 
did the combination of variant alleles in hOGG1 and XRCC3 (OR = 0.52, 95% CI = 0.27-
0.98, P = 0.04). On the contrary, a combination of variant alleles in DSB repair genes 
(XRCC3 rs861539 and XRCC2 rs3218536) resulted in the significant increase of CTAs 
(OR = 2.56, 95% CI = 1.02-6.40, P = 0.05). These results point again to an effect of the 
G allele of XPD Lys751Gln on CTA frequency modulation as stated above. 
For CSAs, again variant alleles in XRCC1 rs25487 and hOGG1 rs1052133 (both BER 
genes) in combination with homozygous variant genotype in XPG rs17655 resulted in 
significantly decreased frequencies of CSAs (OR = 0.22, 95% CI = 0.08-0.66, P = 0.007, 
and OR = 0.72, 95% CI = 0.54-0.97, P = 0.03, respectively). Interestingly, variant G allele 
in hOGG1 rs1052133 in combination with variant alleles in genes involved in NER or 
DSB repair resulted in decreased frequencies of CAs, CTAs and CSAs, despite the fact 
that variant G allele is associated with the lower capacity to repair oxidative DNA damage 
[272]. This phenomenon may be connected with the fact that 8-hydroxy-deoxyguanine 
adducts may block replication fork, thus preventing the accumulation of CAs. 
In summary, CAs arise as a consequence of the interaction between occupational 
exposure to various genotoxicants and individual genotype configuration. In this study, 
we tested the impact of functional SNPs in DNA repair genes on the frequency of CAs. 
Although individual variants in genes encoding DNA repair proteins modulated CAs only 
modestly, several gene-gene interactions evinced either enhanced or decreased CA 
frequencies. As suggested by Melis et al. [273] and now confirmed by us, the complex 
mechanism of CAs accumulation requires complex interplay between different DNA 
repair pathways. However, the mechanism may not be tracked without the knowledge of 
the experimentally proven functional impact of DNA repair gene variants. 
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4.2.2 Finding novel SNPs predisposing to the formation of CAs and 
potentially to cancer 
Based on the results from Publication IV and other previous candidate gene studies which 
have mainly focused on genes important for the maintenance of genome integrity, such 
as DNA repair, mitotic checkpoint and metabolic pathways, as reviewed in Publication 
IX, in the following two publications (Publication V and Publication VI), we designed 
two GWAS. The main goal was to discover previously unknown, potentially functional 
loci predisposing to CAs. These studies were the first GWAS of this nature. 
In the study entitled "Distinct pathways associated with chromosomal aberration 
frequency in a cohort exposed to genotoxic compounds compared to general population." 
by Niazi Y et al. (2019) (Publication V, page 148), we conducted two GWAS on healthy 
individuals in the presence (exposed group) and absence (reference group) of apparent 
genotoxic exposure with the primary aim to explore the genetic basis of the variation in 
CA frequency between individuals and whether it depends on the level and type of 
exposure. 
In the exposed group, the proportion of individuals with high CAtot was 56 %, while it 
was only 29 % in the reference group, and the distribution of CA frequency differed 
significantly between the two groups (P = 4.46 × 10-19). GWAS were performed on both 
groups and several associations at the suggestive level of significance (P ≤ 1 × 10-5) with 
in silico predicted functionality were found for all three CA phenotypes (CSA, CTA and 
CAtot) in both logistic and linear models. Since the samples sets and CA frequency 
differed, and because the CAs are measured as a number of aberrations per 100 cells, we 
used both of these models to evaluate the associations between the SNPs and CA 
frequencies. 
In the reference group, 18 different loci showed an association at the suggestive level of 
significance. In silico analysis predicted functional consequences for five of the loci (see 
Table 2 in Publication V). In the CAtot analysis, logistic regression model implicated the 
locus p15.2 on chromosome 11 with rs10585869 as the top hit. In the linear model, two 
loci 7q11.21 and 8q22.3 showed significant associations and in silico predicted functional 
consequences with top SNPs rs9647884 and rs2293982, respectively. Additional two loci 
5q35.2 and 12q22 were associated with CTAs and CSAs, respectively, in the linear 
model. GWAS on the exposed group revealed 11 associations at the suggestive level of 
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significance. After the in silico analysis, four loci were selected from the CTA and CSA 
linear and logistic models (see Table 3 in Publication V). Both the top SNPs in the CTA 
linear model analysis (rs56217929 at 2q33.3) and CTA logistic model analysis 
(rs10040952 at 5p15.31) almost reached the genome-wide significance. We further 
performed a meta-analysis in an attempt to identify loci predisposing to CAs independent 
of exposure. Three loci had P-values ≤ 1.0 × 10-5, none to moderate heterogeneity between 
the two groups and in silico predictions suggesting functionality. These were rs11792561 
at 9q22.2 in the CAtot linear model analysis, rs2933639 at 5q23.1 in the CTA logistic 
regression model analysis and rs8054859 at 16q12.2 in the CSA logistic regression 
analysis (see Table 4 in Publication V). 
In this study, we identified novel loci that were located in or near genes related to DNA 
repair/DDR and chromatin modulation and chromosome segregation. Interestingly, apart 
from COPRS [274] and FTO genes [275], which were observed in the analysis on exposed 
group and meta-analysis, respectively, all other loci were identified from the reference 
group's analysis. These included PSMA1, UBR5, PMS2P4, STAG3L4, and BOD1 genes 
[276-280]. Besides, several top hits from both groups were located in the genes related to 
tumour progression or suppression. All these SNPs are located within regulatory elements 
with the potential to affect the expression of the respective genes – for detail, see 
Publication V. It is also interesting to note that various SNPs in ITGB3 have also been 
found to be associated with autism aetiology, a disease associated with chromosomal 
abnormalities [281]. Other two loci found associated with autism were identified in the 
CTA analysis of the exposed group. These were 5p15 (rs10040952) [282] and 2q33.3 
(rs56217929) [283] near the KLF7 gene. In the reference group, CAs may have arisen as 
a result of internal factors, reduced DNA repair or epigenetic deregulation. We can 
speculate that the higher burden of CAs induced by exposure to different genotoxic agents 
is not only influenced by individual variability in the genes dealing with different types 
of DNA damage but also in other genes related to tumorigenesis (including genes 
involved in metabolism and transport). Thus, distinct causes of CA increase between 
exposed and reference groups could explain the differences between the GWAS findings. 
The following study entitled "Genetic variation associated with chromosomal aberration 
frequency: A genome-wide association study." by Niazi Y et al. (2019) (Publication VI, 
page 157)was also based on the GWAS approach in investigating SNPs related to CA 
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frequencies. To have a broad insight into the genetic susceptibility associated with CA 
frequency, the sample sets included in this study composed not only of non-exposed and 
differentially exposed individuals but also of newly diagnosed, untreated cancer patients, 
who may represent a population with increased susceptibility to CAs. We first conducted 
the GWAS on discovery sample set followed by replication on two independent sample 
sets (replication 1 and 2). 
Occupational exposure significantly influenced CA frequency in the GWAS discovery 
sample set (P = 1.21 × 10-9). In replication 1, the most significant variable affecting CA 
frequency was cancer status (P = 7.56 × 10-6), while in replication 2, the effect of 
occupational exposure was moderate (P = 0.009). Both logistic and linear regression 
models for the same reasons as in Publication V were applied for the analysis of all three 
CA phenotypes (CSA, CTA and CAtot). No SNP associations at the level of P ≤ 1×10-5 
were found in CSAs. However, it is known that CSAs are affected to a lesser extent by 
chemical mutagens, to which our populations were mainly exposed, as compared to CTAs 
[284]. Altogether 11 loci, six from the CAtot and five from the CTA analysis, were chosen 
for replication and the most significant SNPs with P ≤ 1x10-5 from these loci were selected 
on the basis of in silico analyses (see Table 3 in Publication VI). 
Regarding CAtot, the logistic regression model showed more significant associations than 
the linear model; however, almost all the loci showed similar trends in the linear model 
as well. For all SNPs, except for rs16931167, replication 1 showed ORs on the same 
direction as in the GWAS and the strongest associations in the meta-analysis were for 
rs1383997 at 8q13.3 (OR = 0.6, 95% CI = 0.49-0.73, P = 3.44 × 10-7) and rs2824215 at 
21q21.1 (OR = 1.57, 95% CI = 1.29-1.91, P = 8.7 × 10-6). Replication 2 did not give much 
support for the GWAS associations, and the strongest association in the meta-analysis of 
all populations with P = 4.01 × 10-5 was for rs12002628 at 9q21.13. Rs1383997 and 
rs12002628 are located in the gene related to transient receptor potential (TRP) cation 
channels TRPA1 and TRPM3, respectively. TRP channels regulate the Ca2+ ions 
homeostasis in response to environmental and chemical factors. Any deregulation in Ca2+ 
distribution patterns can promote the signs of cancer development such as proliferation, 
enhanced survival and invasion [285]. The other SNP from the CAtot analysis, rs2824215 
is located in a long intergenic noncoding RNA, and deletion in this locus has been linked 
to autistic features with complex chromosomal rearrangements [286]. Interestingly, two 
 
 57 
other SNPs, which we selected for replication, rs17215792 (2q33.3) and rs2837619 
(21q22.2) are located in the genes associated with autism and Down syndrome, KLF7 
[283, 287] and DSCAM, respectively [288, 289]. 
For the CTA analysis, on the other hand, higher associations were found in the linear 
model as compared to the logistic model. Five SNPs showed an association at the 
suggestive level of significance. Here also, the GWAS and replication 1 showed more 
similar associations than the GWAS and replication 2. In the meta-analysis of the GWAS 
and replication 1, one association, rs983889 at 5p15.1 remained statistically significant at 
the suggestive level (P = 1.06 × 10-5), and no significant associations were observed in 
the meta-analysis of all three populations. Although the SNPs from the GWAS were 
selected based on the linear model, we also calculated the ORs and 95% CIs in the logistic 
model. For the most significant SNP, rs983889, the OR was 0.65 (95% CI = 0.52-0.80) 
in the meta-analysis of the GWAS and replication 1. Rs983889 is an intronic SNP in the 
FBXL7 gene. FBXL7 belongs to F-box proteins, which are involved in phosphorylation-
dependent ubiquitination of proteins and which display proapoptotic activity [290]. 
Incidentally, one of the targets of FBXL7 is the AURKA gene, a known oncogene, 
involved in the regulation of mitosis [291]. During the late G2 phase, AURKA is recruited 
to centrosomes [292] and later on promotes centrosome maturation and bipolar spindle 
formation [293]. Since CTAs also arise during S/G2 phase [171], an indirect involvement 
of AURKA can be anticipated to affect the frequency of CTAs. 
In summary, our GWAS identified new SNPs associated with CA frequency, from which 
three were replicated at the suggestive level of significance in Publication VI. In 
Publication V, these variants were found in genes involved in DDR/repair, segregation of 
chromosomes and chromatin modification. Others were related to apoptosis, cell 
proliferation, angiogenesis and tumorigenesis. Three different variants are directly or 
indirectly related to autism/autistic traits, a condition linked to chromosomal 
abnormalities. In Publication VI, in silico predictions of functional consequences of the 
identified SNPs and their loci revealed that they were directly or indirectly related to 
different cancers. They included genes encoding TRP cation channel proteins, genes 
involved in autism and Down syndrome, and FBXL7, which interacts with AURKA, an 
important regulator of mitosis. Our results suggest a complex interaction of various 
genetic factors responsible for the inter-individual differences in CA frequency in the 
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presence and absence of evident exposure to genotoxins, many of which are still 
unexplored. Due to the sample size, the results of these GWAS are not definitive in terms 
of pointing out the exact rationale behind CAs development, they certainly point towards 
the probable loci that could be involved in the elevated frequency of CAs in the presence 
of environmental stress. Although further functional studies will be warranted to unravel 
the mechanism behind these interactions, the results of these studies help narrow down 
the essential genes and pathways behind them. Identification of new genetic variants for 
the frequency of CAs offers prediction tools for cancer risk in future. 
4.3 DNA repair and its association with cancer susceptibility, 
patients' therapy response and clinical outcome 
The primary aim of last two studies (Publication VII and Publication VIII) included in 
this Thesis was to find differences in DNA repair in colorectal cancer patients which may 
aid in stratifying patients according to predicted therapy response and patients' survival. 
It will lead to an individual approach to patients and may be an attractive target for 
therapeutic intervention strategies. While Publication VII was based on investigating 
genetic variants in DNA repair genes, Publication VIII investigated BER at the functional 
level as BER-DRC along with MSI. 
4.3.1 SNPs in DNA repair genes and their association with cancer 
susceptibility and patients' clinical outcome 
The next hypothesis-based study entitled "Functional polymorphisms in DNA repair 
genes are associated with sporadic colorectal cancer susceptibility and clinical 
outcome." by Jiraskova K et al. (2018) (Publication VII, page 170) was aimed at 
evaluating the relevance of 16 functional SNPs in 12 DNA repair genes (EME1, FAAP24, 
FANCI, MUS81, NEIL3, POLE, POLN, POLQ, RAD51D, REV1, REV3L and RPA1) on 
the risk of colorectal cancer development (in a case-control study) and modulation of 
patients' clinical outcome after cancer diagnosis (in a follow-up study). Selected SNPs 
were tested independently on two sample sets, the discovery and replication sets. 
Regarding the case-control study, the carriers of the variant AA genotype in REV3L 
rs3204953 were observed as associated with an increased risk of colorectal cancer (P = 
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0.006) in the discovery set. SNPs in this gene in association with cancer susceptibility 
were also observed in published literature. The same SNP was recognized to be associated 
with a higher risk of breast cancer in Swedish cohort [294], and different SNPs in REV3L 
gene have been found to be associated with breast, stomach, and colorectal cancer [294-
296]. Apart from the deleterious nature of the protein function, the amino acid change in 
REV3L was in silico predicted to decrease the protein stability [297]. In cancer cell lines, 
the importance of accurate regulation of REV3L expression was demonstrated; while its 
inhibition induced a growth arrest, the overexpression led to increased spontaneous 
mutation rates [298]. A decreased expression levels have also been reported in tumour 
tissue compared to the non-malignant adjacent mucosa in colon cancer [299, 300]. 
Unfortunately, these promising results obtained from the discovery sample set were not 
confirmed in the replication sample set. Nevertheless, since REV3L emerged several 
times as being a significant modulator of patients' OS and EFS in the replication set, we 
suppose that REV3L gene may have an impact on colorectal cancer susceptibility as well 
as on patients' survival and therapy response and further investigations are warranted. 
In the follow-up study, several SNPs revealed to be associated with either patients' 5-year 
OS or EFS by investigating the interactive effects of genotypes and clinicopathological 
parameters using CART analysis. Only a few of these SNPs were shown as significant 
splits more than once in the final structure of the tree, suggesting their potentially greater 
relevance on patients' survival. SNPs in POLQ gene appeared as an optimal split factor 
in OS CART for the discovery set four times (rs1381057, rs3218649 twice, and 
rs3218651), and in the replication set four times as well (rs1381057 twice and rs3218651 
twice (Figure 13). At least nine out of 23 known POLQ SNPs in the human are predicted 
to alter protein function [301], and several SNPs have also been associated with the risk 
of different cancers [294, 302-304]. In addition to the deleterious nature of the protein 
function, the amino acid change in POLQ was in silico predicted to decrease the final 
protein stability. In has been demonstrated that upregulation of POLQ was present in 
different tumour tissues, and this overexpression was in association with the patients' 
prognosis [305-308]. Based on the data from published studies, we suppose the 
significance of adequate POLQ functioning and regulation for tumour suppression. 
Regarding the 5-year EFS CART analysis, NEIL3 rs7689099 revealed twice as the 
optimal split factor in the discovery cohort (Figure 14). Different SNPs in NEIL3 gene 
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were associated with the risk of several cancers [309-311]. Specifically, rs7689099 was 
associated with a decreased risk of differentiated thyroid carcinoma and prostate cancer 
[310, 311]. Similarly, as in previously mentioned REV3L and POLQ, upregulated 
expression levels of NEIL3 were found in tumours of 20 cancer sites, including colorectal 
cancer [312, 313]. The overexpression was further observed in association with the 
progression to distant metastasis in melanoma [314]. The association of the SNP in the 
NEIL3 gene with patients' survival was not detected in the replication sample set. 
However, considering the available data, we propose that the variation of the NEIL3 gene 
also has the relevance for colorectal cancer susceptibility as well as patients' survival and 
therapy response. 
In summary, this study evaluated the association of SNPs in DNA repair genes selected 
by likely functional relevance with colorectal cancer. The data suggested that even amino 
acid substitution causing subtle alterations in the specific proteins that function in DNA 









Figure 13. Overall survival classification & regression trees of colorectal cancer patients from the 
discovery sample set (A) and replication sample set (B). 
Classification & regression tree represents the results of multivariate survival analysis (using Cox regression hazard model). Numbers 
under each node show the total number of cases in a particular subcategory/number of events and percentages of patients with 5-years 














Figure 14. Event-free survival classification & regression trees of colorectal cancer patients from the 
discovery sample set (A) and replication sample set (B). 
Classification & regression tree represents the results of multivariate survival analysis (using Cox regression hazard model). Numbers 
under each node show the total number of cases in a particular subcategory/number of events and percentages of patients with 5-years 
OS. Corresponding Kaplan-Meier curves represent the differences in OS for each node. Abbreviations: 5-FU – 5-fluorouracil, TNM 
– tumour-node-metastasis. 
4.3.2 DNA repair capacity and its association with patients' therapy 
response and clinical outcome 
The study entitled "Base excision repair capacity as a determinant of prognosis and 
therapy response in colon cancer patients." by Vodenkova S et al. (2018) (Publication 
VIII, page 193) was aimed at investigating BER-DRC and MSI in relation to 5-FU 
response of colon cancer patients as potential predictive and/or prognostic biomarker. 
Since BER recognizes and removes mis-incorporated uracil and 5-FU from DNA and 
MMR removes mismatched nucleotides and drives 5-FU-induced cytotoxicity [26,27], 
we thus hypothesized that the deregulation of and individual variation in BER and MMR 
might be significant factors in poor 5-FU response and decreased patients' survival. With 
this in mind, we designed this follow-up study of which the main aim was to investigate 
BER-DRC, further supplemented by MSI status determination in paired samples of 
tumour tissue and non-malignant adjacent mucosa of colon cancer patients. 
This study failed to identify any significant differences overall in the level of BER-DRC 
between these two types of tissue (mean ± SD: 9.91 ± 10.32 vs 10.82 ± 12.01, P = 0.89). 
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However, we observed a significant correlation between BER-DRC in the paired samples 
(rs = 0.68, P < 0.0001). The obtained results were in agreement with previously published 
studies [202, 315]. They may suggest that tumour cells do not become deficient in BER 
during the process of carcinogenesis but rather follow patterns characteristic for each 
individual and are comparable with non-malignant cells of the same origin. Besides, 
stromal cells play an important role in colon cancer development, progression and 
resistance to (mainly targeted) therapy [316]. 
Components of the BER pathway have increasingly been identified as predictive markers 
of cancer risk, prognosis, chemoresistance, and as potential therapeutic targets in a variety 
of cancers [317]. Published evidence also suggested an association between inaccurate 
BER and increased tumour invasiveness in colorectal cancer [318]. In this context, we 
observed the link between increasing BER-DRC tumour/mucosa ratio and advanced 
TNM stage of the disease (Figure 15). Analysis of a panel of BER pathway proteins 
showed their high expressions in gastric cancer patients in association with advanced 
stage and decreased patients' survival [319]. Recently, it has been pointed out that the 
prognostic significance of upregulated BER proteins supports the use of their 
measurement in refining the current TNM staging in colorectal cancer [320]. 
 
 
Figure 15. Differences in BER-DRC ratio between TNM stage II, III and IV of colon cancer. 
BER ratio means a relative value of BER-DRC, calculated as the relative ratio of BER-DRC in tumour tissue over BER-DRC in non- 
malignant adjacent mucosa (i.e. BER-DRC in tumour tissue / BER-DRC in non-malignant adjacent mucosa). Differences in BER-
DRC ratio between different TNM stages were calculated using Wilcoxon Two Sample Test. Abbreviations: BER – base excision 
repair, DRC – DNA repair capacity, TNM – tumour-node-metastasis. 
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Further, in univariate survival analysis, we observed that patients with a higher BER-
DRC than cut-off in non-malignant adjacent mucosa exhibited significantly better 5-year 
OS and RFS (OS: HR = 0.36, 95%CI = 0.18-0.75, P = 0.007; RFS: HR = 0.52, 95%CI = 
0.28-0.97, P=0.04). However, the level of BER-DRC in the tumour was not associated 
with clinical outcomes in our cohort. A possible explanation of this phenomenon might 
lie in a non-selective effect of 5-FU, resulting in adverse toxic side effects. Since colon 
epithelium is one of the most constantly regenerated tissues in the body and displays a 
large number of proliferating cells, it may have increased vulnerability to 5-FU-mediated 
DNA damage accumulation as well. As a consequence, higher BER-DRC in non-
malignant mucosa may deal more successfully with uracil and 5-FU mis-incorporation to 
maintain genome stability and patients with this molecular characteristic may show better 
OS and RFS. 
The prognostic utility of BER-DRC in non-malignant adjacent mucosa was further 
supported by CART survival analysis. The CART analysis explored the interactive effects 
of BER-DRC in paired tissues and MSI, together with clinicopathological data in 
association with 5-year OS and RFS. Patients in TNM stage II + III with good therapy 
response and higher BER-DRC than cut-off in non-malignant adjacent mucosa had 5-
year OS increased by approximately 30 %. Moreover, the survival of these patients was 
even better in the presence of lower BER-DRC than cut-off in tumour tissue (Figure 16). 
These results supported our hypothesis that functional DDR is crucial for the maintenance 
of genome stability in non-malignant cells, whereas the suppression of DNA repair in 
malignant cells may increase the effectiveness of chemotherapy. 
The presence of MSI-high status is a predictive marker for the detection of colorectal 
cancer patients in TNM stage II and III who might not benefit from adjuvant 5-FU 
chemotherapy and thus could reduce the risk of over-treatment [321]. MSI-high tumours 
accounted for 15 % of the whole set of samples, and they were mostly localized in the 
proximal colon (P < 0.0001), which was in accordance with world statistics [322]. 
Interestingly, we did not find any association of MSI-high tumours either with patients' 
and tumour characteristics or with therapy response and survival. 
In summary, BER-DRC represents an integrated marker for evaluation of multistep DNA 
repair processes. As a functional measure of enzyme activity, it complements 
transcriptional and translational measurements of BER genes/proteins. The results of this 
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study suggested that the level of BER-DRC is associated with colon cancer patients' 
survival. Therefore, BER-DRC represents a potential prognostic biomarker, applicable 
for prediction of therapy response and useful for an individual approach to patients. 
 
Figure 16. Overall survival classification & regression tree. 
Classification & regression tree represents the results of multivariate survival analysis (using Cox regression hazard model). Numbers 
under each node show the total number of cases in a particular subcategory/number of events and percentages of patients with 5-years 
OS. Corresponding Kaplan-Meier curves represent the differences in OS for each node. Abbreviations: BER – base excision repair, 




This Dissertation Thesis was performed in response to several unclear and unresolved 
issues of the role of DNA damage and repair in cancer pathogenesis. In this section, 
individual aims of the Thesis are provided by the primary outcomes of the own 
experimental work in light of existing literature and knowledge. 
1) In Publication I, we supported the concept of using CAs in PBLs as a biomarker of 
early carcinogenic effect and clearly suggested the role of elevated CAs (including 
CAtot, CTAs, and CSAs) as a biomarker of cancer susceptibility, mainly breast and 
lung cancer. Colorectal cancer risk was only determined by the subset of CAtot, i.e. 
levels of CTAs. Further, in Publication II, we observed that individuals with longer 
TL in PBLs were at increased risk of breast cancer. Regarding patients' clinical 
outcomes, accumulation of CTAs in PBLs appeared to be associated with decreased 
OS in breast and colorectal cancer patients after their stratification according to 
disease characteristics. While we found the association of elevated CAs with 
telomere shortening in control healthy individuals, cancer patients exhibited no 
relationship between either TL and CA frequencies or TL and age. Results of 
Publication III suggested that altered DSB repair in PBLs is mainly associated with 
colorectal cancer susceptibility. Our results also showed a significant correlation 
between telomere shortening and mutagen sensitivity profile in a pooled group of 
cancer patients; however, the same trend was not detected in a control group. These 
observations added further information to the chain of evidence on the interplay 
between the telomere complex and DSB. 
2) By investigating functional SNPs in DNA repair genes in relation to CAtot, CTAs, 
and CSAs in healthy individuals (Publication IV), we observed an association of 
variant GG genotype in XPD rs13181 with decreased CTA frequency and CT 
genotype in RAD54L rs1048771 with increased CSAs. By addressing pair-wise gene-
gene interactions, we have discovered 14 interactions significantly modulating CAs, 
9 CTAs and 12 CSAs frequencies and NBS1 rs1805794 appeared most often in these 
interactions. However, these gene-gene combinations evinced either enhanced or 
decreased frequencies of CAs, CTAs and CSAs. The GWAS-based Publications V 
and VI indicated several new SNPs associated with CA frequency, from which three 
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were replicated at the suggestive level of significance. These variants were found in 
genes involved in DDR/repair, segregation of chromosomes and chromatin 
modification. Others were related to apoptosis, cell proliferation, angiogenesis and 
tumorigenesis. In silico predictions of functional consequences of the identified 
SNPs and their loci revealed that they were directly or indirectly related to different 
cancers, autism/autistic traits, Down syndrome, and a condition linked to 
chromosomal abnormalities. These results suggest a complex interaction of various 
genetic factors responsible for the inter-individual differences in CA frequency in the 
presence and absence of evident exposure to genotoxins, many of which are still 
unexplored.  
3) Based on the results from Publication VII, we have identified the association of 
several functional SNPs in DNA repair genes with colorectal cancer susceptibility 
and patients' clinical outcome. REV3L rs3204953 was observed to be associated with 
increased susceptibility to colorectal cancer. Further, several other SNPs were shown 
to be associated with patients' OS and EFS using the multivariate survival analysis. 
Our data suggested that even amino acid substitution causing subtle alterations in the 
specific proteins that function in DNA repair pathways may lead to inaccurate DNA 
repair, and thus play a role in colorectal cancer pathogenesis. In Publication VIII, 
we pointed to the importance of studying DNA repair at a functional level, directly 
in tumour and non-malignant tissue to reveal its potential predictive and/or 
prognostic value. The results of this study suggested that the level of BER-DRC is 
associated with long-term survival of colon cancer patients. In accordance with 
published literature, we observed the link between increasing BER-DRC 
tumour/mucosa ratio and advanced TNM stage of the disease. Therefore, BER-DRC 
may represent a potential prognostic biomarker, applicable for prediction of therapy 
response and useful for an individual approach to patients. 
 
This Dissertation Thesis suggested and/or verified several potential candidate biomarkers 
for predicting cancer susceptibility and patients' clinical outcome for further use in 
population monitoring and clinical practice. The majority of them represented already 
discovered biomarkers which were evaluated by well-defined, long-term used and 
validated methods. However, additional studies on larger independent cohorts are needed 
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to replicate our findings. Regarding the future perspectives, taking into consideration the 
fact that cancer represents a complex heterogeneous disease that is caused by the 
combination of several factors, multivariate approaches involving multiple biomarkers 
might contribute to the identification of reliable links between specific genetic/molecular 
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